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ABSTRACT 
Diabetes Miletus (DM) is one of the major health problems in the United States. Despite 
all efforts made to combat this disease, its incidence and prevalence are steadily increasing. One 
of the common and serious side effects of treatment among people with diabetes is hypoglycemia 
(HG), where the level of blood glucose falls below the optimum level. Episodes of HG vary in 
their severity. Nevertheless, many require medical assistance and are usually associated with 
higher utilization of healthcare resources such as frequent emergency department visits and 
physician visits. Additionally, patients who experience HG frequently have poor outcomes such 
as higher rates for morbidities and mortality. 
Although many studies have been conducted to explore the risk factors associated with 
HG as well as others that looked into the level of healthcare utilization and outcomes among 
patients with HG, most of these studies failed to establish a theoretical foundation and integrate a 
comprehensive list of personal risk factors.  Therefore, this study aimed to employ Andersen’s 
health Behavior Model of health care utilization (BM) as a framework to examine the problems 
of HG. This holistic approach facilitates enumerating predictors and examining differential risks 
of the predisposing (P), enabling (E) and need-for-care (N) factors influencing HG and their 
effects on utilization (U) and outcomes (O).  
The population derived from the national inpatient sample of the Healthcare Cost and 
Utilization Project (HCUP) database and included all non-pregnant adult diabetic patients 
admitted to hospitals’ Emergency Departments (EDs) with a diagnosis of HG from 2012-2014. 
Based on the BM framework, different factors influencing HG utilization and outcome were 
grouped under the P, E, or N component. Utilization was measured by patients’ length of stay 
(LoS) in the hospital and the total charges incurred for the stay. Outcome was assessed based on 
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the severity ranging from mortality (the worst), severe complications, mild complications, to no 
complications (the best).  
Structural Equation Modeling (SEM) followed by Decision Tree Regression (DTREG) 
were performed. SEM helped in testing multiple hypotheses developed in the study as well as 
exploring the direct and indirect impact of different risk factors on utilization and outcome. The 
results of the analysis show that N is the most influential component of predictors of U and O. 
This is parallel to what was repeatedly found in different studies that employed the BM. 
Regarding the other two components, P was found to have some effect on O, while E influences 
the total charge. Interaction effects of predictors were noted between some components, which 
indicate the indirect effect of these components on U and O. Subsequently, DTREG analysis was 
conducted to further explore the probability of the different predictor variables on LoS, total 
charge, and outcome. Results of this study revealed that the presence of renal disease and DM 
complications among HG patients play a key role in predicting U and O. Furthermore, age, 
socio-economic status (SES), and the geographical location of the patients were also found to be 
vital factors in determining the variability in U and O among HG patients.  
In conclusion, findings of this study lend support to the use of the BM approach to health 
services use and outcomes and provide some practical applications for healthcare providers in 
terms of using the predictive model for targeting patient subgroups (HG patients) for 
interventions among diabetic patients. Moreover, policy implications, particularly related to the 
Central Florida area, for decision makers regarding how to approach the growing problem of DM 
can be drawn from the study results.     
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CHAPTER 1 : INTRODUCTION 
Diabetes is one of the major health problems in the United States (Diabetes.org, 2014). 
Despite all efforts made to combat this disease, its incidence and prevalence are steadily 
increasing (CDC, 2014). When diagnosed, doctors advise their patients to change their lifestyle, 
improve their eating behaviors, and maintain regular physical exercise (NIDDK, 2014). All these 
efforts aim to achieve better control on the level of glucose in the patients’ blood. However, only 
a few patients succeed in doing so, whereas most require supplementation with medications 
called “glucose lowering medications” (GLM), which help in reducing the amount of glucose 
circulating in their blood to achieve what is known as a state of “glycemic control” (Briscoe & 
Davis, 2006). 
Unfortunately, sometimes the blood glucose level (BGL) falls below the optimum level 
and patients develop an event called “hypoglycemia” (HG) (ADA, 2015). Episodes of HG can be 
mild, moderate, or severe hypoglycemia (SH), depending on the amount of drop in blood glucose 
(BG) below the optimum BGL (Barendse, Singh, Frier, & Speight, 2012). It is well-known that 
HG is usually associated with higher utilization of healthcare resources such as emergency 
department (ED) visits, physician visits, Intensive Care Unit (ICU) transfers, and medications 
(Curkendall et al., 2009). Additionally, patients who experience HG also have poor outcomes 
such as more readmissions, higher morbidity, and higher odds of mortality (Bloomfield et al., 
2012). 
HG is not uncommon among diabetic patients. It is estimated that 25% of hospital 
admissions for diabetes are because of SH (Greco & Angileri, 2004). Therefore, there have been 
many studies conducted to explore the risk factors associated with HG. In addition, many studies 
have looked at healthcare utilization among these patients as well as their clinical outcomes. 
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However, most of these studies lacked a solid theoretical framework and therefore produced 
inconsistent knowledge that did not help to resolve the overall problem. Additionally, previous 
approaches focused on either the risk factors or the utilization and outcomes, without integrating 
different factors into a coherent and comprehensive profile associated with health services 
utilization and outcomes. 
Therefore, this study aims to employ Andersen’s health Behavior Model of health care 
utilization (BM) (Babitsch, Gohl, & von Lengerke, 2012) as a framework to examine the 
problem of HG. This holistic approach helps in determining different risk factors and their 
implications for improving patients’ utilization and outcomes. To achieve this, the study used 
Structural Equation Modeling (SEM) (Weston & Gore, 2006), which is a powerful analytical 
technique that helps in establishing causal sequence, examining multiple research hypotheses, 
and determining the overall goodness of fit of the data to the BM. Plenty of studies used SEM to 
simplify complex relationships between variables as well as to detect any indirect relationships 
between them (Guo, Perron, & Gillespie, 2009). Hence, this study also provides rich information 
to healthcare providers and policy-makers and can assist them in better understanding the 
problem and implementing new approaches to reducing the occurrence of such a serious health 
disorder.   
1.1 Organization of the chapters: 
Chapter One begins with a brief background on diabetes and HG, including the problem 
of HG on the individual level as well as the overall healthcare system. Then, the study problem, 
purpose, and significance are introduced. Afterward, a brief discussion on the theoretical 
3 
framework of the study is presented, followed by a summary of the research hypotheses and 
questions. 
Chapter Two reviews the relevant literature. It outlines a brief history of the BM and 
previous work done that employed the BM. Next, HG risk factors documented in the literature, 
including P, E, and N components, are discussed in detail. Last, previous studies that focused on 
HG utilization and outcomes are presented. 
Chapter Three presents the methodology applied to this study. The research questions, 
design, subjects, and data collection methodology are introduced, followed by a comprehensive 
discussion about variables and their operationalization. Then, it presents power analysis and 
sample size justification. Last, the methodology section presents SEM, measurement models, 
validation of the models, and decision tree regression (DTREG) analysis. 
Chapter Four presents the results of the analysis including descriptive statistics, 
correlation analysis, Confirmatory Factor Analysis (CFA), Structural equation model, and the 
results from the DTREG analysis. At the end of the chapter, test results of each of the five 
hypotheses of the study are revealed.  
Chapter Five provides a discussion on the study findings, with a special focus on the 
three main endogenous variables: LoS, total charge, and outcome. Afterward, theoretical, policy, 
and practical implications of the study are discussed. Finally, major limitations for the study are 
noted and followed by pertinent recommendations for future research.  A conclusion is drawn 
from this theory-based investigation of HG and its impact on utilization of health services and 
outcomes of diabetes care. 
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1.2 Background  
1.2.1 Diabetes background:  
Diabetes is a national health problem in the U.S. that affects about one in every ten 
Americans, which is about 30 million people (Diabetes.org, 2014). That number is expanding as 
there are about 1.7 million new cases of diabetes diagnosed annually (CDC, 2014). From an 
economic perspective, diabetes imposes a substantial burden on society. In 2012, the estimated 
total economic cost of diabetes care in the U.S. was $245 billion (CDC, 2014). Medical 
expenditures incurred by diabetic patients are estimated to be $13,700 per year, which is 
approximately 2.3 times higher than non-diabetic patients (ADA, 2013), with an average 
patient’s out-of-pocket expenditure of $1,373 per year (Cunningham & Carrier, 2014). Hospital 
inpatient care for diabetic patients is considered to be the largest component of their medical 
expenditures, which is about 43% of the total medical costs related to diabetes (ADA, 2013). 
According to the American Association of Clinical Endocrinologists (AACE) and American 
Diabetes Association (ADA), more than 20% of all hospital inpatient days were related to the 
care of diabetic patients (Moghissi et al., 2009).  
The two primary types of diabetes are type I diabetes mellitus (T1DM) and type II 
diabetes mellitus (T2DM). T1DM used to be called “juvenile diabetes” or “insulin-dependent 
diabetes” because it mostly occurs in younger people who require insulin. It only represents 5-
10% of all diagnosed diabetes (NIDDK, 2014). On the other hand, T2DM, also referred to 
“adult-onset diabetes” or “non-insulin-dependent diabetes,” is the most common type that 
usually affects middle-aged or older people. About 90-95% of people with diabetes are affected 
by T2DM (NIDDK, 2014).  
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1.2.2 Hypoglycemia background 
The primary aim of long-term management of diabetes is to lower the amount of glucose 
circulating in the blood, or BGL (Briscoe & Davis, 2006). However, when BGL falls below the 
optimum range, the person is considered to be having an episode of HG (Barendse et al., 2012). 
The ADA defines hypoglycemia as “a condition characterized by abnormally low BGL, usually 
less than 70 mg/dl” (ADA, 2015). HG can be mild, moderate, or severe, based on the amount of 
drop in BGL below the 70 mg/dl. There are no clear demarcations between each of those 
categories, but according to AACE and ADA, many clinicians consider a drop in BGL below 50 
severe hypoglycemia (SH) (Moghissi et al., 2009). Acute symptoms that are usually associated 
with hypoglycemia are tachycardia, sweating, anxiety, shakiness, dry mouth, and hunger (ADA, 
2005; Ahrén, 2013; Barnett et al., 2010). However, the number of symptoms and their severity 
are correlated with the acuity of the HG episode. 
1.2.3 The problem of hypoglycemia 
One of the considerably prevalent complications among diabetic patients is HG. A 2015 
systematic review and meta-analysis of population-based studies revealed that the incidence of 
HG episodes among diabetic per person, per year is about 20 times (Edridge et al., 2015). While 
not all HG events are considered severe and many can be self-managed, often, patients will seek 
medical assistance by visiting the ED, and they will sometimes end up being admitted into the 
hospital. The Centers for Disease Control and Prevention (CDC) estimated that nearly 300,000 
ED visits for adults in the U.S. occurred in 2011, with HG being the first-listed diagnosis and 
diabetes as another diagnosis (CDC, 2014). Analysis of data from the 1993–2005 National 
Hospital Ambulatory Medical Care Survey showed that there were about five million ED visits 
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because of HG, which means that the ED visit rate was 34 (95% CI 30–37) per 1,000 diabetic 
patients with HG (Ginde, Espinola, & Camargo, 2008).  
Hospitalization of ED-treated HG cases is also common. A study published in the Journal 
of the American Medical Association (JAMA) found that almost one-third (29.3%, CI, 21.8%–
36.8%) of the cases presented to ED with HG resulted in hospitalization (Geller et al., 2014). 
Ginde et al. also found that one-fourth of ED-treated HG cases were admitted to the hospital 
(Ginde et al., 2008). There are other studies showing that diabetics with HG have higher odds of 
being hospitalized (Hsu et al., 2013; Jakubczyk & Rdzanek, 2015). Analysis of 10 years’ worth 
of records from 1998-2009 from the National Health Insurance Research Database of Taiwan 
with over 77,600 T2DM patients showed that individuals with HG had 3.45 times higher risk of 
being hospitalized (Hsu et al., 2013). The utilization of healthcare services seemed to be higher 
among those with more severe HG. A recently published systematic review and meta-analysis 
estimated that about 10% of SH required hospital treatment in the ED or admission (Jakubczyk 
& Rdzanek, 2015). Davis, et al. (2010) conducted a longitudinal observational cohort study with 
data from 1999-2006 focusing on diabetic patients and found that 24.2% of SH cases requested 
ambulance attendances only, 43.9% visited the ED, and about 31.8% needed to be admitted to 
the hospital. Another Canadian study with data from 2004-2009 found that patients who 
experienced previous episodes of SH had higher risks for hospitalizations than those who never 
experienced SH episodes (HR 2.80, 95% CI 1.55–5.06) (Majumdar et al., 2013).  
In addition to the increasing odds of ED visits and hospital admissions among diabetic 
patients with HG, those who were admitted to the hospital tended to stay an average of three 
days longer than others who did not have HG (Curkendall et al., 2009; Gómez et al., 2015; 
Signorovitch et al., 2013; Turchin et al., 2009). Moreover, they were at a higher risk of being 
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transferred to the intensive care unit (Blosch, Chernoff, & Nijjar, 2010; Farrokhi et al., 2012; 
Garg, Hurwitz, Turchin, & Trivedi, 2013). Readmission rates among HG patients tended to be 
higher among diabetics who experienced HG (Quilliam, Simeone, & Ozbay, 2011; Zapatero et 
al., 2014). Because of all of the above-mentioned utilization channels related to HG, the cost 
associated with the treatment of HG cases was found to be tremendously higher than those with 
no HG (Curkendall et al., 2009; Quilliam, Simeone, Ozbay, & Kogut, 2011; Zhang et al., 2010). 
Another problem of HG identified by Bloomfield, et al. (2012) was that those who 
experienced HG usually developed unpleasant medical complications and poor outcomes. For 
example, HG was consistently found to be associated with cardiovascular (CV) complications 
such as MI, stroke, and arrhythmias studies (Goto, Arah, Goto, Terauchi, & Noda, 2013; Yeh et 
al., 2015). Other common consequences of HG included falls and fall-related fractures, sepsis, 
and seizures. Additionally, inpatient mortality rates among HG patients were 7-12% higher than 
the rates of diabetics without HG (Curkendall et al., 2009; Gómez et al., 2015). There are also 
many other long-term consequences of HG that are not included in this study. These include 
issues that affect the quality of life (QoL) such as absence from work and decreased productivity 
at work, dementia, and impairment of cognitive functions (Bloomfield et al., 2012; Lopez, 
Annunziata, Bailey, Rupnow, & Morisky, 2014). 
1.3 The Study problem 
There are numerous well-conducted studies on the risk factors for HG as well as the 
utilization and outcomes of HG events (see Appendix A). Studies that focused on risk factors 
usually included national data and concentrated on the incidence and prevalence of the HG 
events. In addition, many of these studies were very specific and focused only on the HG risks 
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among certain medications, specific age groups such as the elderly, or specific comorbidities 
such as kidney diseases. Moreover, several studies looked only into one type, either T1DM or 
T2DM. All of these studies provided useful results about the most relevant risk factors of HG. 
However, the review showed that these studies lack a holistic approach, which integrates risk 
factors into a coherent predictive model with the level of utilization and/or outcomes. 
Furthermore, most of these studies did not include a control group. The analyses of the risk 
factors were descriptive in nature or included minimal use of regression analysis or predictive 
modeling. 
On the other hand, studies that examined the level of utilization, such as LoS or cost of 
care, or the outcomes, provided details about these elements. However, they typically did not 
include any risk factors, or they focused only on some specific ones such as specific GLMs used 
and their correlation with LoS or specific age group and their level of utilization and outcomes. 
Moreover, neither type of study applied the BM, which integrates the predictors with utilization 
and outcome in a full and comprehensive model.  
The burden that HG imposes on diabetic patients and the overall healthcare system is 
enormous. At the patient level, diabetics with HG usually have higher out-of-pocket 
expenditures, greater risk for short-term and long-term complications, and higher mortality rates 
than other diabetics who do not have HG. In addition, HG episodes usually require 
hospitalizations of those patients and also are linked to longer hospital stays and higher mortality 
risks (Jakubczyk & Rdzanek, 2015). On the other hand, HG has a massive impact on the 
economy as well as resource utilizations of the healthcare system. Therefore, there is a pressing 
need for studies that assist in providing the bigger picture of this problem. According to the 
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AACE and ADA consensus statement on inpatient glycemic control, there are several topics 
related to HG that need further exploration (Moghissi et al., 2009). These include: 
(1) What is the profile of inpatients at greatest risk for severe hypoglycemia?  
(2) What are the short-term and long-term outcomes of patients experiencing severe 
hypoglycemia?  
(3) What are the true costs of inpatient hypoglycemia? 
1.4 The Study Purpose 
The literature is loaded with multiple risk factors that contribute to the development of 
HG events that require hospitalization. These studies also show that different factors play 
different roles in the severity of the attack as well as the prognosis and outcomes (Berkowitz et 
al., 2013). However, there is very limited knowledge about the correlation between different risk 
factors of HG and their impact on utilization of healthcare services or their correlation with the 
overall outcome of hospitalization of diabetic patients with HG. Therefore, the primary goal of 
the study is to identify the relative importance of the determinants in predicting utilization and 
outcome among those patients and to examine the mechanisms and interactions between those 
factors. Furthermore, the study seeks to explore the magnitudes of the main effects of each of the 
predictor variables and their interaction effects on health services use and outcomes. 
1.5 Significance of the Study 
1.5.1 Policy Relevance 
Diabetes is a huge problem in Florida with over 13% of adults having been diagnosed 
with diabetes, and about 39% having prediabetes (ADA, 2016; Floridacharts.com, 2016). The 
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number of ED visits with a diagnosis of diabetes has increased by 47.2% from 2009 to 2014 and 
the number of hospitalizations increased by about 16% (Floridahealth.gov, 2017). According to 
the ADA, total annual diabetes medical expenses in Florida are estimated to be $24.3 billion 
(ADA, 2016). HG is the second most common complication among DM patients regarding the 
percent of discharges in Florida (22.36% of discharges) and the costliest in terms of total charges 
(Floridahealth.gov, 2017). Therefore, this study will be useful to health planners and policy 
makers in identifying diabetes patients who are at higher risks for developing HG events and 
those who are susceptible to more utilizations and worse outcomes. Consequently, special 
education and awareness programs can be tailored to target those at higher risks. In addition, 
community-specific initiatives can be implemented based on the patient characteristics in each 
community affected by HG and other related complications. 
1.5.2 Practical Application 
The primary contribution of this study is to operationalize and test the multi-level or 
nested characters of risk factors as well as the associated resources utilizations and health 
outcomes among patients who develop HG. Therefore, the study could aid understanding of the 
level of hospital care utilization as well as the overall treatment outcomes among diabetic 
patients who might develop HG. In addition, the study shows the magnitude of the effect of each 
of the factors as well as the presence of any interaction among the factors. This will help 
healthcare providers, who see patients during clinic visits or in the hospital at the time of 
admission, to pay particular attention to diabetic patients who have any of these factors and 
potentially prevent some of the unwanted outcomes. Consequently, those patients might 
consume fewer healthcare services and achieve better outcomes. 
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1.6 Theoretical framework: Andersen’s Behavioral Model of Health Services Use (BM) 
One of the most widely acknowledged models that is used as an explanatory framework 
in identifying predictors of health care utilization is the BM, which was developed in the 1960s 
by Ronald M. Andersen (Aday & Andersen, 1974; Andersen, 1995; Andersen & Aday, 1978; 
Andersen & Newman, 1973; Chern, Wan, & Begun, 2002; Wan & Soifer, 1974). The BM is a 
multivariate model that integrates three different individual determinants of health services 
utilization: Predisposing (P), enabling (E), and need-for-care (N) component.  
The later revised model incorporated a critical component for researchers and policy 
makers, which is outcome (Andersen, 1995). Outcome is an important dimension that provides a 
broader understanding of utilization behavior since it is considered a subsequent predisposing 
component to the individual’s future healthcare utilization. 
Predisposing component (P): Ps are “individual characteristics which exist prior to the 
onset of specific episodes of illness” (Andersen & Newman, 1973). The propensity to utilize 
medical services differs from one patient to another, and it is subject to a variety of social and 
demographic factors (Wan & Soifer, 1974). Based on the previous studies that examined risk 
factors of HG, this study includes the following most commonly used risk factors under (P): age, 
gender, and ethnicity (Bloomfield et al., 2012) (Table 1). In addition, dementia, depression, 
tobacco use, alcohol use, and drugs abuse will be included as they were repeatedly considered in 
many studies that employed the BM (Babitsch et al., 2012). 
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Table 1. List of study variables 
Predisposing Enabling Need-for-Care Utilization Outcome 
1. Age 
2. Sex 
3. Ethnicity 
4. Dementia 
5. Depression 
6. Tobacco use 
7. Alcohol use 
8. Drugs Abuse 
1. Insurance status 
2. Socioeconomic 
Status 
3. Hospital Location 
4. Patient Location 
1. DM Complications  
2. Type of DM 
3. BMI underweight 
4. Hypertension 
5. Hyperlipidemia 
6. Liver Failure 
7. Renal Disease 
8. Uncontrolled DM 
9. Cancer 
10. Charlson 
Comorbidity Index 
(CCI) 
1. Hospital LoS 
2. Cost 
1. Severity of 
the adverse 
outcome 
 
Enabling component (E): For people who have the predisposing component, there are 
means that enhance or inhibit their use of services (Aday & Andersen, 1974; Wan & Yates, 
1974). This study considers the most relevant factors related to HG for (E): medical insurance 
type, socio-economic status (Bloomfield et al., 2012). In addition, two other factors are 
considered: the geographical location of the patient, and the geographical location of the 
hospital, as they both repeatedly showed a strong influence on utilization (U) and outcome (O) 
among HG patients (Table 1). 
Need-for-care component (N): This refers to the level of illness that the individual has 
(Chern et al., 2002). Parallel to the presence of predisposing and enabling conditions, illness is 
required to be perceived by the patient or his family in order for the patient to proceed and use 
health services, such as a clinic or hospital visit (Andersen & Newman, 1973; Wan & Soifer, 
1975). Among all other factors, (N) is considered “the most immediate cause of health service 
use” (Andersen & Newman, 1973). While there are plenty of elements that can be included 
under (N), this study includes a group of factors that were commonly found to impact (U) and 
(O) among diabetic patients who develop HG: DM complications, type of DM, BMI 
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underweight, hypertension, liver failure, kidney disease, uncontrolled DM, and the Charlson 
Comorbidity Index (CCI) (Table 1). 
1.7 Research Hypotheses 
Based on the literature summarized in Appendix A, all three components (P, E, and N) 
play a role in determining the variability in utilization (U) and outcomes (O). For example, old 
age, low income level, and the presence comorbidities might increase the individual’s length of 
stay, health care costs, readmissions, patient falls, and mortality (Berkowitz et al., 2013; 
Johnston, Conner, Aagren, Ruiz, & Bouchard, 2012; Nirantharakumar et al., 2012). However, 
the level of importance of each of these factors might vary. Another issue is that LoS does not 
always correlate with the total cost. For example, some patients might have a shorter hospital 
stay while the total costs associated with the intensity of care provided to them are very high. In 
contrast, some patients might stay longer times in the hospital with some reasonable total costs 
associated.  
Therefore, the first three hypotheses for this study include:  
Ha1: The magnitude of different components varies with regard to determining the LoS 
among patients who develop HG. 
Ha2: The magnitude of different components varies with regard to determining the total 
cost among patients who develop HG. 
Ha3: The magnitude of different components varies with regard to determining the 
outcome among patients who develop HG. 
As mentioned earlier, (N), which represented mainly as the level of illness, is the most 
important element in determining the level utilization. Therefore, plenty of studies focused only 
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on risk factors related to (N), such as the presence of kidney disease and its effects on HG and 
showed that kidney disease is directly linked to higher costs and LoS (Yu, Lin, Chang, Sung, & 
Kao, 2014). So, the fourth hypothesis for this study is: 
Ha4: The need-for-care component is the most important component of the predictors of 
use, while the effects of other predictors are being simultaneously considered. 
Last, certain studies showed that interaction effects among different predictor variables 
existed. For example, older patients who use Sulfonylurea have longer LoS and have a higher 
risk for adverse events such as falls or fractures (Deusenberry, Coley, Korytkowski, & Donihi, 
2012). By considering this, the fifth hypothesis for this study is: 
Ha5: There are statistically significant interaction effects (e.g., P*N, N*E, and E*N) of 
predictor variables on utilization and outcomes. 
1.8 Research Questions 
RQ1. Which component is most important in determining the LoS among patients who 
develop HG, when other factors are held constant?  
RQ2. Which component is most important in determining the total cost among patients who 
develop HG, when other factors are held constant?  
RQ3. Which component is most important in determining the outcome among patients who 
develop HG, when other factors are held constant?  
RQ4. Is the need-for-care the most important predictor of use, while the effects of other 
predictors are simultaneously considered?  
RQ5. Do the predictor variables (P, E, and N) show any significant interaction effects on 
utilization and outcomes?  
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CHAPTER 2 : LITERATURE REVIEW AND THEORETICAL 
FRAMEWORK 
2.1 Review of Conceptual/Theoretical Perspectives 
The behavioral model of health services utilization, which is often referred to as the 
“health behavior model” (BM) (Babitsch, Gohl, & von Lengerke, 2012), was developed by 
Ronald Andersen in the late 1960s as a framework to help understand which factors influence 
families to use health services (Figure 1) (Andersen, 1995). Since then, the BM has undergone 
multiple revisions and modifications until the last revised model, which was published in 1995 
(Aday & Andersen, 1974; Andersen, 1995; Andersen & Aday, 1978; Andersen & Newman, 
1973). 
 
Figure 1. The Initial Health Behavior Model (Andersen, 1968) 
 
The most recent model embraced two major aspects: the focus on individuals rather than 
families and the addition of outcome. Because of the heterogeneity among family members, it 
was more appropriate to employ the model at the individual level. Furthermore, the revised 
model helps in providing more accurate reflections about the different factors. On the other hand, 
including outcome in the model represents a dynamic correlation between the after-effects of 
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utilizing health services. It also denotes a feedback loop of possible future use of health care 
services (Figure 2) (Shepherd, Locke, Zhang, & Maihafer, 2014). 
 
Figure 2. The revised Health Behavior Model (Andersen, 1995). 
 
The fundamental principles of the BM rely on categorizing an individual’s determinants 
of health service utilization into three categories: (1) predisposing component; (2) enabling 
component; (3) need-for-care (Andersen & Newman, 1973). These factors individually and 
collectively influence the individual’s level of health services use (Conwell & Boult, 2008). 
Individual characteristics that pre-exist before the onset of illness are considered predisposing.  
Age, sex, and ethnicity are typical examples of factors under the predisposing component. On the 
other hand, the enabling component refers to the means and resources available that enable the 
individual to use the services (Gelberg, Andersen, & Leake, 2000). For example, income and 
insurance coverage facilitate the use of health services for patients. Last is the need-for-care, 
which is considered the most immediate cause for utilization (Aday & Andersen, 1974). Need-
for-care refers to the individual’s illness level and may include elements such as comorbidities 
and diabetes type.  
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The BM provides a reliable framework to examine health services utilization because it 
can be applied for multiple purposes (Gochman, 1997). One of the major advantages of the BM 
is that it works as an integrated theoretical framework that is practical and applicable to a broad 
range of studies. Another advantage is that it arrays different factors that influence utilization 
into three categories. This helps researchers in conceptualizing relevant predictors of utilization 
rather than just listing all factors without any order. Lastly, it facilitates testing multiple research 
hypotheses generated from a wide-array of predictors and utilization variables (Gochman, 1997). 
Recently, various configurations have been developed among different studies that 
employed the Andersen’s BM (Graham, Hasking, Brooker, Clarke, & Meadows, 2017). While 
they all provide the same concept regarding the three components: predisposing, enabling, and 
need-for care, the difference is about how they impact utilizations (Stiffman et al., 2001). The 
figure below shows the most common configurations for the BM:  
 
Figure 3. Common Configurations of the Health Behavior Model (Graham et al., 2017). 
 
Reviewing different studies and how they employed the BM model reveals that two 
major elements usually define the most appropriate model to use: study context and sample 
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characteristics (Babitsch et al., 2012; Graham et al., 2017). Thus, reviewing the literature is key 
to determining how different components are related to each other and which configuration is 
relevant to the study.   
2.1.1 Previous work on Andersen’s Model 
Since the BM was introduced, it has frequently been used in different studies that 
examined the level of health care utilizations (Babitsch et al., 2012). These studies investigated a 
broad spectrum of diseases such as diabetes, hypertension, depression, heart diseases, cancer, 
and many others, with the level of patients’ utilizations of healthcare services (Appendix B). 
While the BM has been used to examine wide varieties of illnesses including diabetes, it was not 
applied to examining factors influencing HG care utilization and outcomes. 
With diabetes, the BM was employed in plenty of studies that examined the utilization of 
care among diabetic patients. Most of these studies examined either T2DM alone or T1DM and 
T2DM. Some studies examined general utilization among diabetes patients including the 
frequency of ED visits, the number of hospitalizations during a certain amount of time, and the 
number of visits to doctors’ clinics (Gamble & Chang, 2014; Gucciardi, DeMelo, Booth, 
Tomlinson, & Stewart, 2009; Jayawant, 2008; Ou et al., 2012). A few others focused on the 
utilization of specific services such as the eye care exam (Baumeister et al., 2015; DeLawnia, Lu, 
& Zo, 2014). Utilization among diabetics was also studied to examine the presence of any racial 
differences (Chandler & Monnat, 2015; Shenolikar, 2006; Yeboah-Korang, Kleppinger, & 
Fortinsky, 2011). Diabetics’ adherence to medication and self-care and their impact on utilization 
was also examined in other studies (Patel et al., 2015; Yamashita, Kart, & Noe, 2012). Last, the 
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level of healthcare costs associated with diabetes care was investigated in several studies (Hu, 
Shi, Pierre, Zhu, & Lee, 2015; Jayawant, 2008; Shenolikar, 2006). 
As mentioned earlier, the BM was employed in a broad range of issues other than 
diabetes. Two of the most frequently examined types of diseases using BM are mental and 
psychological illnesses. Several studies examined the influence of mental diseases and 
psychological issues on healthcare utilization (Blaskowitz, 2014; Kilany, 2014; Ko, 2015; 
Rhoades et al., 2014; Springer, 2015). Another common issue was examining the utilization level 
among older populations (Clement, 2015; Manski et al., 2013; Scheetz, 2010; Snih et al., 2006; 
Wolinsky, Stump, & Johnson, 1995) or racial differences in utilization (Bazargan, Bazargan, & 
Baker, 1998; Wilkinson-Lee, 2008). There were some other studies that specifically examined 
the impact of having insurance coverage on utilization (Akobirshoev, 2015; Gelberg et al., 2000; 
Mallya, 2006; Roberge, 2008; Shepherd et al., 2014).  
Similar to diabetes studies, most of the studies that examined mental and psychological 
illnesses considered hospitalizations, LoS, ED visits, and clinic visits as measures of utilization. 
However, not all of the above-mentioned studies used SEM and some employed only the 
traditional multivariate techniques, which lack the ability to demonstrate the presence of any 
interaction effects among different predictors. Moreover, the use of traditional multivariate 
techniques does not help detect any interaction effects among different the predictors. 
2.1.2 Studies that employed the BM using SEM 
In contrast to the studies mentioned above, there are some others that employed BM to 
examine the level of utilization and applied SEM as the primary method of analysis.  Although 
these studies examined different arrays of health conditions, two predominant factors were found 
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to influence the level of utilization. The first predictor of utilization was the level of illness, 
which was usually the most significant component in most of these studies (Brook, Lee, Balka, 
Finch, & Brook, 2014; Chern et al., 2002; Stein, Andersen, Robertson, & Gelberg, 2012; Tan, 
2009; Wan & Soifer, 1974). The other common predictor was the presence of health insurance 
coverage, which is usually included in the enabling component (LaHousse, 2009; Stein, 
Andersen, & Gelberg, 2007; Tan, 2009; Wan & Soifer, 1974). 
2.2 Prior studies on HG risks factors, utilization, and outcome 
Numerous studies examined HG risk factors and provided rich information about the 
relevant factors that lead to hypoglycemia (see Appendix A). Moreover, many others examined 
the level of utilization and/or the health outcomes among patients with HG. However, these 
studies either looked at the risk factors and/or the utilization and outcomes, which means that 
they did not employ a holistic approach that integrates the risk factors with the level of utilization 
and outcomes among those patients. Also, these studies did not use SEM.  
The following sections will discuss the two primary different types of studies: studies that 
examined HG risk factors only and studies that examined HG utilizations and outcomes. 
Relevant findings from these studies will be discussed in a later section (sections 2.3-2.6) when 
reviewing the different factors. 
2.2.1 Studies examined risk factors to hypoglycemia 
Plenty of studies examined risk factors to HG among diabetic patients and provided 
comprehensive knowledge about the most relevant risk factors. Some included large databases 
with multiple years to determine the incidence of HG and the most significant risk factors 
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(Bruderer et al., 2014; Edridge et al., 2015; Ginde et al., 2008; Giorda et al., 2015; Sämann et al., 
2013). Other studies looked at drug-related risks of HG (Czech et al., 2015; Murad et al., 2012; 
Murad et al., 2009), while others either examined patients on insulin regimens or those on oral 
GLMs (Gold, Frier, MacLeod, & Deary, 1997; Kostev, Dippel, & Rathmann, 2014; Kostev, 
Dippel, & Rathmann, 2015; Sonoda et al., 2015; Weinstock et al., 2015), and some others 
focused on patients with continuous glucose monitoring (Cox, Gonder-Frederick, Ritterband, 
Clarke, & Kovatchev, 2007; Fiallo-Scharer et al., 2011). There are also some other studies that 
focused on older populations only (Bruderer et al., 2014). Although these studies provided useful 
information about the risk factors related to HG (sections 2.3-2.6), they focused only on HG 
events that occurred in the outpatient settings.  
There are other studies that investigated risk factors of HG among hospitalized diabetic 
patients (Abdelhafiz, Bailey, & Sinclair, 2012; D'Netto, Murphy, Mitchell, & Dungan, 2015; 
Dendy et al., 2014; Deusenberry et al., 2012; Elliott, Schafers, McGill, & Tobin, 2012; Farrokhi 
et al., 2012; Gómez et al., 2015; Lin et al., 2010; Pathak et al., 2015; Schloot et al., 2016). 
Similar to the studies of outpatients, they did not examine the level of utilization or patient care 
outcomes (sections 2.4-2.6).  
2.3 The predisposing component (P) 
A systematic review of studies using BM from 1998–2011 showed that there was a broad 
range of variables utilized in these studies. However, few “key variables” were found to be 
repeatedly used (Babitsch et al., 2012). For example, age, sex, and ethnicity were used under (P), 
whereas indicators such as income and health insurance were used under (E). Because this study 
is the first to examine HG and because of the nature of secondary data, it will focus only on the 
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key variables to be able to have a solid understanding about HG. Therefore, this study will 
include the following risk factors under (P): age, ethnicity, gender, depression, dementia, tobacco 
use, alcohol use, and drug abuse. 
2.3.1 Age 
Age is consistently reported to increase the risk of HG in most studies. A recent study 
published by the ADA, which included an observation of over 900,000 patients with diabetes 
from 2005 to 2011, found that the rate of HG significantly increases with age (Pathak et al., 
2015). Another population-based cohort study in Canada, which included more than 85,000 
patients from 2004 to 2009, also found that age substantially increased the risk of HG among 
diabetic patients (Majumdar et al., 2013). A sensitivity analysis of 8,767 type 2 diabetic patients 
in China who were recruited between 1995 and 2007 found that old age is an independent 
predictor for SH (Kong et al., 2014). The hazard ratio per 10 years was found to be 1.50 (1.24–
1.81). Another study that included documents from eight hospitals regarding HG at their EDs 
found that for every five-year increase in age, the odds of SH among T2DM patients  increased 
by 30% (OR: 1.3, 95% CI 1.20-1.45) (Liatis et al., 2015). 
Older people usually experience alterations in their metabolism, become more vulnerable 
to malnutrition, and frequently have other comorbidities (Lin et al., 2010). Therefore, the risk of 
HG among older diabetics increased with GLMs. For example, sulfonylureas, an oral GLM, was 
repeatedly found to increase the risk of HG among older diabetics. A 2012 nested case-control 
study in a tertiary care academic medical center that included hospitalized patients aged 65 years 
and older found that those elderly diabetics were at increased risk for sulfonylurea-related HG 
(OR 3.07, 95% CI 1.67–5.63) (Deusenberry et al., 2012). Insulin also is a strong GLM that is 
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usually associated with a high risk for developing HG events among older diabetics (OR 1.04, 
95% CI 1.02–1.08) (Farrokhi et al., 2012). A recent study by Geller, et al., (2014) that 
investigated a national database from 2007-2011 found that older diabetics on insulin have twice 
the risk for ED visits and five times the risk of hospitalization due to hypoglycemia. 
2.3.2 Ethnicity 
Ethnicity refers to “a concept that incorporates social, religious, linguistic, dietary, and 
other variables to identify individual persons and populations” (Witzig, 1996). While race is 
usually used to classify people by biological features such as skin color, ethnicity is typically 
more concerned with cultural characteristics such as language and food habits (Caprio et al., 
2008).  Therefore, it is more appropriate to examine ethnicity differences when examining 
chronic illnesses such as DM (Schwartz, 2001) than it is to study race. 
Regarding DM, a recent report by the CDC shows that there are differences  among 
ethnicities for diabetes prevalence in the U.S. (CDC, 2014). The highest group was found to be 
Native Americans with 15.9%, followed by African Americans 13.2%, Hispanics 12.8%, Asian 
Americans 9%, and last are the non-Hispanic whites with only 7.6%. However, a national study 
on 2012 data that included over 70,000 diabetic patients found that Hispanics have the highest 
odds of HG episodes when compared to whites and African Americans (Lopez et al., 2014). 
Another cross-sectional analysis of a random sample of adults in the Kaiser Permanente 
Northern California diabetes registry using data from 2005–2006 showed that the odds of 
developing HG are 35% and 33% higher in Latinos and African Americans, respectively, than 
Whites (Berkowitz et al., 2014). Regarding hospitalization among DM patients, a recent study on 
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eight Southeastern States showed the existence of racial disparities in DM hospitalization among 
rural Medicare beneficiaries (Wan, Lin, & Ortiz, 2016). 
2.3.3 Gender  
A systematic review of predictors and consequences of SH showed mixed findings about 
gender (Bloomfield et al., 2012). However, when considering utilization, women were repeatedly 
found to use more health services than men used across studies that employed BM on different 
kinds of diseases (Babitsch et al., 2012). Likewise in diabetes, men usually consumed fewer 
healthcare services than women did (OR 0.96, 95% CI 0.86-1.91) (Gamble & Chang, 2014). 
Analysis of data from 1993–2005 from the National Hospital Ambulatory Medical Care Survey 
shows that ED visit rates are higher among diabetic females (4.0 per 1,000 ED visits, 95% CI 
3.5-4.5) than males (3.4 per 1,000 ED visits, 95% CI 3.0-3.8) (Ginde et al., 2008). Similarly, a 
study using the 2004-2008 MarketScan® database found that the odds of ED visits among 
T2DM males are lower than they are for females (OR 0.82, 95% CI 0.78-0.85) (Simeone & 
Quilliam, 2012). Correspondingly, hospital admissions related to HG were lower for males than 
for females (OR 0.84, 95% CI 0.73–0.96) (Quilliam et al., 2011). 
In addition to the gender differences among diabetics’ healthcare utilization, females who 
develop SH usually had higher utilization as well. It has been found that symptomatic HG in 
T2DM (OR 1.08, 95% CI 0.97–1.20) (Berkowitz et al., 2014) as well as in T1DM (IRR 1.52, 
95% CI 1.33–1.74) (Giorda et al., 2015) was more common among women . Surprisingly, the 
overall in-hospital mortality was higher among males. Additionally, a retrospective study using a 
national database of hospitalized Japanese diabetic patients from 2008–2012 that reviewed 22.7 
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million discharge records showed that in-hospital mortality among females is lower than it is for 
males (OR 0.637, 95% CI 0.551 -0.736) (Sako et al., 2015). 
2.3.4  Dementia  
Dementia is defined as “a general term for a decline in mental ability severe enough to 
interfere with daily life” (alz.org, 2017). It has been  a measure considered under (P) in multiple 
studies that employed the BM for diseases other than HG (Babitsch, Gohl, & von Lengerke, 
2012). Concerning its relationship with HG, several studies confirmed that dementia has a 
positive correlation with HG among diabetic patients (Bruce et al., 2009; Feil et al., 2011; 
Feinkohl et al., 2014; Yaffe et al., 2013). A recent systematic review and meta-analysis 
examined the interaction between HG and cognitive impairment in elderly patients treated with 
GLMs among studies conducted between 2005-2015 and found that patients with dementia have 
a higher risk of developing HG with a pooled odds ratio (95% CI 1.25, 2.06)  (Mattishent & 
Loke, 2016). Another recent systematic review on predictors and consequences of severe HG in 
adults with diabetes concluded that dementia is a risk factor for severe HG (Bloomfield et al., 
2012). Similarly, a recent review article on diabetes, dementia, and HG also indicated that 
multiple studies showed that dementia increases the odds of developing severe HG (Meneilly & 
Tessier, 2016).  
Plenty of other well-recognized studies also showed a strong correlation between 
dementia and HG. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) study, which included more than 11,000 
T2DM patients, higher cognitive function was significantly associated with a lower risk for 
developing HG (HR 0.93, 95% CI 0.87 to 0.99) (Zoungas et al., 2010). In contrast, severe 
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cognitive dysfunction was found to significantly increase the risk of severe HG (HR 2.10, 95% 
CI 1.14–3.87; p = 0.018) (de Galan et al., 2009). In the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) study, which was done at 52 clinical sites in North America with about 
3,000 T2DM patients, lower baseline cognitive scores were found to be a predictor of an 
increased likelihood of clinically significant HG over the following years (Launer et al., 2011; 
Meneilly & Tessier, 2016; Punthakee et al., 2012). Similar findings were reported in the 
Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, which included more 
than 12,500 patients (Meneilly & Tessier, 2016; Riddle, 2015). Moreover, a large longitudinal 
cohort study that included 16,667 T2DM patients who were followed up for 27 years from 1980-
2007 found that the fully adjusted dementia HR among patients with one HG episode was 1.42 
(95% CI, 1.12-1.78), and among those with 2 or more HG episodes, the HR was 2.36 (HR 2.36, 
95% CI, 1.57-3.55) when compared to those with 0 episodes (Whitmer, Quesenberry, & Selby, 
2009).  In Germany, a large retrospective study of 32,545 patients from 1,072 practices found 
that dementia increases the adjusted odds for developing HG among T2DM (1.49; 1.31-1.69) 
(Kostev, Dippel, & Rathmann, 2014).  
Some studies tried to explore why patients with dementia tend to have higher odds of 
HG, especially among older diabetic patients. The Fremantle diabetes study examined more than 
300 older DM patients and concluded that the inability to self-manage medications among 
patients with dementia might be the main reason for the development of HG (HR 4.17, 95% CI 
1.43–12.13) (Bruce et al., 2009). Another retrospective cohort study of national Veterans Affairs 
(VA) administrative/clinical data and Medicare claims that included about 16,000 older T2DM 
veterans with dementia between 2008-2009 found that in addition to the inability to self-manage 
medications, those patients had difficulties following prescribed regimens, showed significant 
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weight loss that is usually related to changes in their eating habits such as low appetite, and 
demonstrated lower capacity to recognize and respond properly to symptoms (Thorpe et al., 
2015).  
2.3.5  Depression  
It is also referred to as “major depressive disorder” or “clinical depression”, which is “a 
mood disorder that causes a persistent feeling of sadness and loss of interest” (Mayoclinic.org, 
2017). Similar to dementia, depression also has been used in different studies that employed the 
BM under (P) (Babitsch et al., 2012). Regarding its relationship to HG, a 2012 systematic review 
(Bloomfield et al., 2012) as well as other reviews confirmed that depression significantly 
increases the odds of developing HG among diabetic patients (Barendse et al., 2012; Jafari & 
Britton, 2015). Another large 2015 study was conducted to examine the association of HG with 
fall-related outcomes among older T2DM patients from 2008-2011 (Kachroo et al., 2015). The 
Kachroo et al., study included more than 1.1 million T2DM patients’ records and found that the 
percentage of dementia among patients who had HG was twice what it was among those without 
HG. Very similar results were shown in another observational cohort study that was conducted 
from 2005 to 2011 and included more than 900,000 diabetic patients  (Pathak et al., 2015). That 
study found that the risk of severe HG was 50% higher among depressed patients when 
compared to others with no depression (P < 0.001). Last, the ORIGIN trial that included over 
12,500 patients found that the HR for HG among depressed patients was 1.28 (1.11-1.48, 
P<0.001) (Meneilly & Tessier, 2016; Riddle, 2015). 
Studies with smaller samples also provided comparable results (Green, Fox, & Grandy, 
2012; Williams, Pollack, & DiBonaventura, 2011). A longitudinal cohort study of 4,117 diabetic 
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patients found that the HR for HG is higher among depressed patients when compared to the 
non-depressed (HR 1.42, 95% CI, 1.03–1.96) (Katon et al., 2013). The study also found that the 
number of HG episodes was higher among those depressed patients (OR 1.34, 95% CI, 1.03–
1.74). Another study that included over 3,800 T2DM patients found that depression is three 
times greater among those who have a history of HG (Tschope et al., 2011).  
All the findings mentioned above match the ones that were conducted in other European 
countries. In Germany, a study included more than 32,500 T2DM patients found that the odds of 
HG among depression patients were 1.24 (95% CI 1.13-1.35) (Kostev et al., 2014). Another 
smaller study in Germany of 420 patients also found that depression was associated with Severe 
HG (Hermanns, Kulzer, Krichbaum, Kubiak, & Haak, 2005). In Belgium, a 2016 longitudinal 
study of over 43,000 patients from 20% of all Belgian hospital beds confirmed that depression 
was a significant risk for HG (Chevalier, Vandebrouck, De Keyzer, Mertens, & Lamotte, 2016).  
Interestingly, numerous studies reported possible correlations between HG in diabetes, 
depression, low income, and lower educational attainment (Berkowitz et al., 2014). This 
relationship explains why diabetic patients with depression usually have suboptimal self-care, 
including being less adherent to recommended diet, exercise, and foot care as well as the 
pervasive lack of regular meals (Katon et al., 2013; Kostev et al., 2014; Zhang et al., 2015). In 
addition, many other studies found that those patients are more likely to have issues with their 
medication-taking behavior  (Katon et al., 2013; Krass, Schieback, & Dhippayom, 2015; Zhang 
et al., 2015) as well as poor adherence to blood glucose monitoring (Katon et al., 2013; Kostev et 
al., 2014). A large study of more than 38,000 veterans with diabetes who had at least three 
outpatient visits in the previous year found that the rates for secondary prevention of diabetes 
such as retina examination and foot sensory examination were significantly lower among those 
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with depression (Conwell & Boult, 2008; Desai, Druss, & Perlin, 2002). All of the above 
findings point toward a positive correlation between HG and depression in diabetes patients. 
2.3.6 Tobacco use  
Smoking significantly increased the risks of developing T2DM, according to a 2015 
systematic review on the relationship of active, passive, and quitting smoking with T2DM (Pan, 
Wang, Talaei, Hu, & Wu, 2015). For those who were already diagnosed with T2DM, it was 
found that the RR for developing repeated HG events among smokers is 1.34 (1.02-2.02, P<0.05) 
(Akram, Pedersen-Bjergaard, Carstensen, Borch-Johnsen, & Thorsteinsson, 2006). Another 
study found that history of smoking, regardless of current smoking status, increased the odds of 
developing severe HG episodes among T2DM patients (adjusted HR 1.43, 95% CI 1.09-1.788, 
P<0.01) (Zoungas et al., 2010). Among T1DM, smokers also had higher odds of developing HG 
when compared to non-smokers (OR 2.40, 95% CI 1.30-4.40) (Hirai, Moss, Klein, & Klein, 
2007).  
On top of the risk of developing HG, smoking adversely affected diabetic patients by 
increasing the risks for other comorbidities as well as mortality. A 2013 systematic review and 
meta-analysis with bias analysis on the association between severe HG and risk of cardiovascular 
disease among T2DM patients showed that smokers had a higher RR for HG and CV diseases 
(2.37, 95% CI 1.61-3.47) than others who were non-smokers (RR 1.91, 95% CI 1.59-2.29) (Goto 
et al., 2013). Regarding other comorbidities, both T1DM and T2DM smoker patients 
significantly differed from non-smokers in terms of the presence of microalbuminuria as well as 
microvascular and macrovascular complications (Nilsson, Gudbjörnsdottir, Eliasson, Cederholm, 
& Steering Committee of the Swedish National Diabetes, 2004). In the Translating Research Into 
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Action for Diabetes (TRIAD) study, examining records of 8,334 patients revealed that smoking 
increased the all-cause mortality among T2DM (HR 1.59, 95% CI 0.94-1.63) (McEwen et al., 
2012). 
2.3.7 Alcohol use  
The use of alcohol has been included under (P) in many previous studies (Babitsch et al., 
2012). Alcohol has also been examined as a risk factor for HG, and the findings affirm that 
relationship (Barendse et al., 2012). A 2012 narrative review on the impact of HG on the quality-
of-life and related patient-reported outcomes in T2DM found that alcohol consumption increased 
the risk of developing HG among T2DM patients (Barendse et al., 2012; Braak et al., 2000). A 
more recent systematic review and meta-analysis of population-based studies that included 46 
studies of a total of 532,542 T2DM patients identified alcohol as a risk factor for developing HG 
(Edridge et al., 2015). In the Fremantle diabetes study, daily alcohol consumption was found to 
increase the odds for HG among T2DM patients (HR 1.38, 95% CI 0.55-3.46) (Davis et al., 
2010). In another study, the annual incidence of HG was found to be positively correlated with 
the amount of alcoholic drinks per week (Miller et al., 2010).  
There are many answers as to how alcohol consumption might lead to HG among 
diabetic patients. Alcohol reduces the endogenous production of glucose, and it inhibits the 
process of gluconeogenesis (Cryer, Davis, & Shamoon, 2003). Moreover, inebriation itself 
affects the level of self-care and adherence to recommended diet or medications (Cryer et al., 
2003). Hence, the consumption of alcohol facilitates the occurrence of HG episodes among 
diabetic patients. 
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2.3.8 Drug abuse 
While there are plenty of studies that have considered drug abuse as an element in (P) for 
different diseases (Babitsch et al., 2012), only a few studies have examined its relationship with 
HG among diabetic patients. One large nested case-control analysis study in the U.K. between 
1998 and 2012 found that tramadol use by patients increased the risk of HG requiring 
hospitalization (Fournier, Azoulay, Yin, Montastruc, & Suissa, 2015). Another study found a 
significant dose-response relationship between HG and the use of methadone (Flory, Wiesenthal, 
Thaler, Koranteng, & Moryl, 2016). Desai et al. (2002) found that there was a significant 
difference in the use of retina examination, foot sensory examination, and other secondary 
prevention care of diabetes among diabetic patients with mental disorders who abused drugs and 
others who did not. These findings might be one way to explain the relationship between drug 
abuse and HG (Conwell & Boult, 2008). 
2.4 The Enabling component (E) 
As mentioned earlier, key variables related to HG are examined in this study, including 
socio-economic status (SES), insurance coverage, and the geographical location of the patient 
and the hospital. 
2.4.1 Socio-economic Status (SES) 
Lower SES has been regularly found to be correlated with diabetes. Results from the 
National Health Examination and Nutrition Examination Survey showed that patients who were 
at a lower SES were more likely to have diabetes than those with higher SES (OR 2.1, 95% CI 
1.1–4.0) (Seligman, Bindman, Vittinghoff, Kanaya, & Kushel, 2007). A 2011 systematic review 
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and meta-analysis also revealed the same findings (RR 1.40, 95% CI 1.04-1.88) (Agardh, 
Allebeck, Hallqvist, Moradi, & Sidorchuk, 2011). Children who were in lower SES families 
were also found at a higher risk of developing diabetes (HR 1.3; 95% CI=0.7, 2.6) (Maty, James, 
& Kaplan, 2010). The incidence of diabetes among unemployed adults was also found to be 
higher than it was for those who were employed (OR for men 2.9; 95% CI 1.9-4.4; OR for 
women 1.7, 95% CI 0.8-3.7) (Kumari, Head, & Marmot, 2004). The TRIAD study showed that 
all-cause mortality was also higher among low SES T2DM patients (fully adjusted HR 1.80, 95% 
CI 1.36-2.38) vs. others with a higher SES (fully adjusted HR 1.20, 95% CI 0.91-1.58) (McEwen 
et al., 2012). 
In addition to the risk of developing diabetes, the odds of HG also increased among the 
low SES group because of low health literacy, food insecurity and prolonged fasting, lack of 
access to quality health care, and inability to afford BG monitoring devices (Berkowitz et al., 
2013; Duran-Nah, Rodriguez-Morales, Smitheram, & Correa-Medina, 2008; Nelson, Brown, & 
Lurie, 1998; Seligman et al., 2011). A 2013 systematic review published in the Journal of Health 
Service Research found that lower SES independently increased the risk of HG among adults 
with diabetes (Berkowitz et al., 2013). The Canadian Journal of Diabetes also published a 
systematic review on T1DM that also found a significant correlation between low SES and HG 
(Sawka et al., 2007). A recent study examined the association between HG and low SES and 
found that diabetics with low SES have about twice the risk of developing HG when compared to 
others with a higher SES (16% vs. 8.8%) (Berkowitz et al., 2014). Hospital admissions related to 
HG were also found to be higher among people with lower SES (OR 1.26, 95% CI 0.99 to 1.61) 
(Wild et al., 2010). One reason for this might be because those with a lower SES were 
consistently found to have lower rates of regular doctors’ follow-ups, screenings, and 
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preventions (Babitsch et al., 2012; Brechner, Howie, Herman, Will, & Harris, 1993; Brown et 
al., 2004; Broyles, McAuley, & Baird-Holmes, 1999; Chen, Kazanjian, & Wong, 2008; Conwell 
& Boult, 2008; Thode, Bergmann, Kamtsiuris, & Kurth, 2005). 
2.4.2  Insurance coverage 
Most studies that employed the BM found that the presence of insurance coverage 
significantly increased the likelihood of using health services (Babitsch et al., 2012) and people 
with healthcare coverage were more likely to participate in diabetic management programs (OR 
1.08, 95% CI 0.76-1.54) (Gamble & Chang, 2014). Rates of ED visits due to HG varied among 
different insurance coverage types. Analysis of National Hospital Ambulatory Medical Care 
Survey data from 1993–2005 showed that the ED visit rate per 1,000 people with diabetes is 
higher in public insurance vs. private and self-pay (5.8 vs. 2.6 and 2.2) (Ginde et al., 2008).  
There were also differences in the characteristics of patients and their levels of 
utilizations of health care services among different insurance providers. Medicaid patients 
usually had more severe chronic medical conditions and more comorbid conditions (Adelmann, 
2003). Therefore, these coexisting medical conditions lead to higher costs and service usage rates 
among Medicaid patients when compared to others covered by other health insurance providers 
(Bailey, Wan, Brunt, & Somes, 2001; Conwell & Boult, 2008; Ou et al., 2012). A systematic 
literature review that was conducted to determine the relationship between low SES and severe 
HG among T1DM patients found that people under Medicaid had twice the risk of HG-requiring 
medical assistance than others who were covered by other insurance providers (OR 10.2, 95% 
CI) (Sawka et al., 2007).  
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2.4.3 Geographical location of the patient and the hospital 
This variable has been used consistently in many studies that employed the Andersen BM 
(Aday & Andersen, 1974; Babitsch et al., 2012). Likewise, it has been used in many studies that 
focused on HG among urban vs. rural diabetic patients from different aspects such as their level 
of ED utilizations, regular physician follow-ups, regular diabetes-related screening and 
prevention measures, and the degree of diabetes goal-attainments.  
Generally, urban areas have lower odds of diabetes HG events when compared to rural 
areas. Kostev et al. (2014) found the odds ratio is 0.74 (0.68–0.80), even after controlling for 
demographics and comorbidities. Data from over five million ED visits from 1993-2005 
analyzed by Ginde et al. (2008) showed that ED visits with HG are higher in non-urban areas 
(4.5 per 1,000 ED visit, 95% CI 3.0-6.1) vs. 3.5 per 1,000 (95% CI 3.1-4.0) in urban areas. 
Another recent study in Taiwan also found that the level of severe HG requiring medical 
assistance was higher among those not living in urban areas (Chen, Yang, Huang, Chen, & Hwu, 
2015). 
Regarding the differences in the frequency of regular doctor visits, follow-ups, 
screenings, and preventions, the systematic review conducted by Babitsch et al., (2012) of 
studies from 1998-2011 that utilized the BM found that residents of urban areas were more likely 
to be adherent to these practices than others who live in the countryside. Other studies also 
showed that usually there were fewer healthcare services in the countryside than there were in 
urban areas (Broyles et al., 1999; Thode et al., 2005). Another large study with 30,589 Medicare 
diabetic patients also showed that patients living in rural areas received almost half as much 
outpatient care and were less likely to receive the recommended tests, screenings, and prevention 
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measures when compared with others who live in larger urban areas (Rosenblatt et al., 2001). 
Many other studies on diabetic patients found similar results, and therefore, patients in smaller 
towns were usually less likely to attain their recommended goals (Andrus, Kelley, Murphey, & 
Herndon, 2004; Conwell & Boult, 2008; Unger, Warren, Canway, Manderson, & Grigg, 2011; 
Weiner, Garnick, Fowles, Lawthers, & Palmer, 1995). 
2.5 The Need-for-Care component (N) 
Based on the review of previous studies’ findings, this study includes the following key 
variables, which are usually found to be correlated to HG: DM complications, type of DM, 
underweight, hypertension, liver Failure, Kidney disease, uncontrolled DM, and the Charlson 
Comorbidity Index (CCI). 
2.5.1 Type of DM  
The odds of developing HG episodes among diabetic patients with T1DM are known to 
be higher than those with T2DM (Cariou et al., 2015). Nevertheless, most patients seen in the ED 
with HG are T2DM (Leese et al., 2003). This is because the prevalence of T2DM is much higher 
than T1DM (Cryer, 2008; Jafari & Britton, 2015). A recently published systematic review and 
meta-analysis shows that there is not a significant difference in the overall resources’ utilization 
among patients with T1DM and T2DM who develop SH (Jakubczyk & Rdzanek, 2015). 
However, the same study found that patients with T1DM tend to have higher estimates of 
professional medical treatment such as doctor consultation or calling an ambulance than T2DM 
tend to have (23.61% vs. 15.54%). On the other hand, the overall hospital admissions because of 
HG seemed to be higher among T2DM than T1DM (15.28% vs. 8.6%). Another study on 5,026 
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diabetic patients admitted in 2010 focusing only on SH found more admissions among T1DM 
than T2DM (21% vs. 5.1%, P = .000) (Dendy et al., 2014). In that study, the OR for T1DM was 
found to be 3.43 (95% CI 1.81-6.49). 
2.5.2 Diabetes Complications 
Diabetes is a chronic disease that can lead to several complications if it is not properly 
managed and controlled (Mayoclinic.org, 2017). The Mayo Clinic study (2017) showed that 
common long-term complications included cardiovascular diseases including micro and macro-
vascular complications, nerve damage (neuropathy), kidney damage (nephropathy), eye damage 
(retinopathy), foot damage, and skin problems. Several studies, including the 2012 systematic 
review by Bloomfield et al. reported that diabetes complications such as nephropathy, 
retinopathy, and neuropathy were considered independent risk factors for severe HG (Bloomfield 
et al., 2012; Kachroo et al., 2015; Malabu, Vangaveti, & Kennedy, 2014; McEwen et al., 2012). 
Williams et al. (2012) found that confirmed hypoglycemia was three-to-four times more likely to 
occur among those diabetic patients who reported neuropathy than others.  
2.5.3 Uncontrolled Diabetes  
Uncontrolled diabetes happens when a diabetic patient shows a consistently high blood 
glucose level that is above the recommended target (ADA, 2009). Usually, long-term 
uncontrolled diabetes leads to several complications that affect the heart, blood vessels, eyes, 
kidneys, and the nerves (Amiel et al., 2015). In contrast, tight glycemic control among particular 
groups of patients usually contributes to HG (Bloomfield et al., 2012). Elderly, underweight, or 
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patients who take certain kinds of GLMs are at a higher risk for developing HG if they are under 
intensive blood glucose control (Edridge et al., 2015; Jafari & Britton, 2015).  
2.5.4 Chronic Kidney Disease (CKD) 
Renal insufficiency is usually caused by a disease in the kidney and recognized with an 
elevation in serum creatinine level or decrease in “estimated glomerular filtration rate” (eGFR) 
(Bloomfield et al., 2012). It is considered one of the major risk factors for hypoglycemia in 
patients with or without diabetes (Abdelhafiz et al., 2012; Moen et al., 2009). Diabetic patients 
with CKD, who develop HG are usually found to have higher mean serum creatinine levels 
(Kilpatrick et al., 2014; Lee et al., 2015) and lower eGFR (Brian & Simon, 2012; Schloot et al., 
2016). Insulin also increases the risk of HG among diabetics with CKD. Therefore, appropriate 
adjusting of the dose of insulin is recommended in those high-risk patients (Baldwin et al., 2012; 
Farrokhi et al., 2012).  
Several studies showed that the odds of developing HG episodes increase among diabetic 
patients with CKD (Duran-Nah et al., 2008; Kostev et al., 2014; Pathak et al., 2015). A 
retrospective cohort study with data from 70 hospitals found that diabetics who developed HG 
had higher odds of comorbidity with CKD (OR 28.4, 95% CI 27.4-29.4) than had those with no 
HG (OR 11.5, 95% CI 11.3-11.7) (Curkendall et al., 2009). Another study on 5,026 diabetic 
patients admitted in 2010 showed that the odds of having CKD with HG were statistically higher 
(OR 69.1% vs. 46.9%, P<.001) than they were for those with diabetics with no HG (Dendy et al., 
2014). Hsu et al. (2013) also found that CKD was independently associated with HG (OR 3.26, 
95% CI 2.76–3.86). Therefore, the rate of HG among patients with CKD was higher than it was 
for those with no CKD (10.72 vs. 5.33 per 100 patient-months) (Moen et al., 2009). 
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The severity of CKD highly impacted the severity and frequency of HG episodes (Moen 
et al., 2009). Renal failure (RF), a more advanced stage of CKD (Kidneyfund.org, 2016), was 
found to cause 26% higher HG episodes (OR 1.26, 95% CI 1.16-1.37) (Kostev et al., 2014). 
Curkendall et al. (2009) also found that diabetics with RF were more likely to have HG than 
those without RF (OR 3.5, 95% CI 3.0-4.1) vs. (OR 1.2, 95% CI 1.1-1.3). Similarly, Quilliam et 
al. (2011) found the odds ratios of T2DM admissions for HG and RF to be 3.10 (95% CI 2.05-
4.67).  
2.5.5 Liver disease 
Liver diseases have been commonly found as a comorbidity among diabetic patients with 
HG.  A retrospective cohort study with data from 70 hospitals found that diabetics who 
developed HG had higher odds of comorbidity with liver diseases (OR 2.2, 95% CI 1.8-2.7) 
compared to (OR 2.0, 95% CI 1.9-2.1) those with no HG (Curkendall et al., 2009). Another 
nested case-control study with a large database from 2004-2008 reported that liver disease was 
associated with HG-related ED visits (OR 1.55, 95% CI 1.30-1.84) (Simeone & Quilliam, 2012). 
Liver cirrhosis, a late stage of fibrosis of the liver, was also found to be a common 
comorbidity. A study derived from the National Health Insurance Research Database between 
1998-2009 with over 77,000 T2DM patients in Taiwan found that liver cirrhosis was 
independently associated with HG (OR 1.71, 95% CI 1.17–2.48) (Hsu et al., 2013). Another 
study on 5,026 diabetic patients admitted in 2010 found statistically higher proportions of 
cirrhosis among patients with SH (14.8% vs. 7.2%) compared to the non-SH group (Dendy et al., 
2014). 
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2.5.6 Hypertension 
Hypertension is a very common comorbidity found among diabetic patients. It is 
estimated that 71% of adults with diabetes have blood pressure over 140/90 (CDC, 2014). A 
positive correlation was usually found between HG and the presence of hypertension (Duran-
Nah et al., 2008; Moore, Li, Hung, Downs, & Nebeker, 2009). The high blood pressure might 
have been caused by the kidney damage associated with diabetes. Hsu et al. (2013) also found 
that hypertension was independently associated with HG among patients with T2DM (HR 1.75, 
95% CI 1.57–1.96). 
2.5.7 Malignancy 
Many studies reported that malignancies were usually found in diabetic patients who 
presented with HG. A consecutive cohort study of 8,767 T2DM patients in China between 1995-
2007 found that the incidence of all-site cancer in patients with SH was higher than it was for 
those without SH (13.4 vs. 6.4%) (Kong et al., 2014). Liatis et al. (2015) also reported that 
cancer was independently associated with SH among T2DM patients (OR 3.21, 95% CI 1.64–
6.29). Likewise, Hsu et al. (2013) found that cancer was independently associated with HG in 
T2D patients (OR 2.73, 95% CI 2.12-3.50). Abdelhafiz et al. (2012) found that HG patients were 
more likely to be diagnosed with cancer than were others with no HG (10% vs. 3.5%, P = 0.04).   
2.5.8 Hyperlipidemia 
Hyperlipidemia is a condition that is usually found among diabetic patients (Rowe et al., 
2015), and the relationship between hyperlipidemia and HG have been documented in several 
studies (Lopez, Bailey, & Rupnow, 2015).  A 2013 systematic review and meta-analysis with 
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bias analysis study found that T2DM patients with dyslipidemia have a higher RR for developing 
HG and cardiovascular diseases (RR 1.93, 95%CI 1.70-2.18) (Goto et al., 2013). Kachroo et al.  
(2015) found in their 2015 study of over 1.1 million T2DM patients that dyslipidemia is the 
second most common comorbidity (39.4%) found in HG patients. In the TRIAD study, it was 
found that diabetic patients with a history of dyslipidemia had an increased risk of all-cause 
mortality when compared to their counterparts (McEwen et al., 2012). A large 2015 study was 
conducted to examine the association of HG with fall-related outcomes among older T2DM 
patients from 2008-2011(Kachroo et al., 2015). The study included more than 1.1 million T2DM 
patients’ records and found that the percentage of dyslipidemia among patients who have HG 
was twice the rate shown among those without HG. 
2.5.9  Low Body Mass Index (BMI) 
BMI is a more appropriate technique than measuring the weight alone because it 
considers the height of the person as well as the weight. It is calculated by dividing the 
individual’s weight in kilograms by the square of height in meters. Based on the value, the 
person is categorized as underweight (BMI<18.5), normal weight (BMI 18.5–24.9), overweight 
(BMI 25–29.9), or obese (BMI>30) (nhlbi.nih.gov, 2016). BMI is inversely related to HG. 
Higher levels of BMI have been found to be associated with lower numbers of HG episodes 
among diabetics, while lower BMI levels have been consistently found to be a risk factor for HG 
among diabetic patients. Therefore, dose adjustments for GLMs is recommended based on the 
BMI level of each diabetic patient (Elliott et al., 2012; Kilpatrick et al., 2014; Olveira et al., 
2015; Sako et al., 2015; Schafers, Naunheim, Vijayan, & Tobin, 2012; Schloot et al., 2016).  
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A large epidemiological analysis of more than 10,000 diabetic patients showed that 
patients with a BMI of 30 or more had a 35% lower incidence of HG than those with less than 25 
BMI (HR 0.65, 95% CI 0.5 to 0.85). Another study that included more than 11,000 patients 
recruited from 215 centers in 20 different countries between 2001-2003 found that each unit 
increase in the BMI was associated with a 5% decrease in risk of HG (HR 0.95, 95% CI 0.93-
0.98) (Zoungas et al., 2010). Giorda et al. (2015) examined T1DM patients only and found 
similar odds associated with HG (IRR 0.95, 95% CI 0.94–0.97). In contrast, Kong et al. (2014) 
also conducted a study on a consecutive cohort of 8,767 T2DM patients in China between 1995-
2007 and found that 1 kg/m2 increase in the BMI was associated with 5% reduction in SH risk. 
In-hospital HG-related mortality also appeared to be higher among those with low BMI. Analysis 
of the National Inpatient Database in Japan from 2008–2012 with 22.7 million inpatients’ 
records focusing on HG among diabetic patients revealed that the highest mortality was among 
underweight (BMI<18.5) diabetics with HG (OR 2.345, 95% CI 1.918-2.868) (Sako et al., 2015).  
2.5.10 Charlson Comorbidities Index 
The Charlson Comorbidity Index (CCI) is the most commonly used index, and it was 
developed and validated as a measure of predicting in-hospital mortality (Charlson, Pompei, 
Ales, & MacKenzie, 1987; Huang et al., 2014; Quan et al., 2011). The most recent revised CCI 
consists of 17 comorbidities and, depending on the mortality risk associated with each condition, 
each is assigned a score from one to six, and the total score for all comorbidities reflects the CCI 
score (Charlson et al., 1987; Roffman, Buchanan, & Allison, 2016).  
Numerous studies concluded that the higher the CCI score among diabetic patients, the 
higher the odds of developing HG (Curkendall et al., 2009; Kostev et al., 2014; Kostev et al., 
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2015; Lopez et al., 2014; Moore et al., 2009; Pathak et al., 2015; Signorovitch et al., 2013). 
Bruderer et al. (2014) found that patients with a CCI score between four and six had higher odds 
for experiencing HG (OR 3.44, 95% CI 2.87-4.13), and the odds were even higher among those 
with a CCI of seven or more  (OR 8.18, 95% CI 5.71-11.72) when compared to others with a one 
to three CCI score.  
Higher CCI scores also aggravate the adverse outcomes that follow HG (Abdelhafiz et 
al., 2012). Additionally, Yeh et al. (2015) found that those with HG were at higher risks for 
developing CV complications when their CCI  were higher. In another study, which focused in 
falls related to HG, Malabu et al. (2014) reported that the odds for falls following HG increased 
among diabetic patients with higher CCI. Several other studies found that HG-related mortality 
was higher among those with higher CCI (McEwen et al., 2012; Monami et al., 2007; Sako et al., 
2015; Zapatero et al., 2014). 
Besides poor outcomes associated with higher CCI, utilization for healthcare services 
among those patients were significantly higher than their counterparts. This includes the number 
of hospitalizations, ED visits, OPD visits, readmissions, LoS, total medical costs, and diabetes 
care-related costs (Ou et al., 2012; Quilliam et al., 2011; Zapatero et al., 2014). Ou et al. (2012) 
also found that those with higher CCI scores were usually less adherent to their antidiabetic 
medications. 
2.6 Studies examined the utilization and/or outcomes among HG patients 
In contrast to the above studies, many studies focused on the level of utilization and/or 
outcomes among diabetic patients without much attention to the risk factors associated with it. 
These studies were focused either on patients who developed HG in outpatient settings or on 
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those who developed HG in the hospital. Studies that examined HG episodes in outpatient 
settings usually focused on the level of healthcare utilization alone (Davis et al., 2010; Duran-
Nah et al., 2008; Geller et al., 2014; Gu et al., 2015; Heller, Frier, Herslov, Gundgaard, & 
Gough, 2016; Home, Fritsche, Schinzel, & Massi-Benedetti, 2010; Liatis et al., 2015; Majumdar 
et al., 2013; Mier et al., 2012; Quilliam et al., 2011; Quilliam et al., 2011; Simeone & Quilliam, 
2012; Solomon et al., 2013; Williams et al., 2012) or outcomes only (Kong et al., 2014; Simon et 
al., 2015). Few others investigated utilization and outcomes together (Cariou et al., 2015; Sako et 
al., 2015). As anticipated, clinic visits, the number of ED visits, the frequency of 
hospitalizations, and LoS were the most common measures used in these studies to gauge the 
level of utilization in diabetic patients who developed HG as an outpatient. On the other hand, 
mortality and quality of life were usually used to measure outcomes. 
Regarding studies that focused on HG among hospitalized patients, most either included 
both utilization and outcomes (Brodovicz et al., 2013; Chevalier et al., 2016; Curkendall et al., 
2009; Turchin et al., 2009; Zapatero et al., 2014) or outcomes only (Olveira et al., 2015; 
Vriesendorp, DeVries, Rosendaal, & Hoekstra, 2008). Among these studies, LoS and cost were 
the two measures that usually were used for utilization, while mortality was the most common 
measure used for outcomes. There were also other measures for outcomes used such as 
readmission, septic shocks, falls, and fall-related fractures. 
2.6.1 HG Utilization (U) 
Based on the literature related to HG and other studies that employed the BM on other 
illnesses, the two most commonly used indicators for (U) are: hospital LoS and cost. This study 
includes those two indicators as measures for (U) among hospitalized HG patients. 
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2.6.1.1 Hospital LoS 
Diabetic patients were usually found to stay longer in the hospital than were non-
diabetics (Moghissi et al., 2009). Among diabetic patients, those who had an HG event while 
hospitalized were consistently found to have had longer LoS than others without HG have had 
(Brodovicz et al., 2013; Geller et al., 2014; Gómez et al., 2015; Jakubczyk & Rdzanek, 2015; 
Nirantharakumar et al., 2012; Turchin et al., 2009; Zapatero et al., 2014). A retrospective cohort 
study using a large database from Spain from 2005-2010 found that HG among hospitalized 
patients was significantly associated with a 24% increase in the odds of longer stays (OR 1.24, 
95% CI 1.15-1.35). (Zapatero et al., 2014). Gómez-Huelgas et al. (2015) also found a strong 
association between HG and LoS (HR 2.036, 95% CI 1.862-2.227).  
Numerous studies sought to find the average difference in LoS among HG and non-HG 
diabetic patients. They found that the average LoS among diabetic patients who developed HG 
was three days longer than it was for others who did not. Curkendall et al. (2009) reported 3.0 
days more among HG patients (95% CI 2.8-3.2). Gómez-Huelgas et al. (2015) found that the 
average LoS among HG patients was 12 days vs. nine days among non-HG patients. 
Signorovitch et al. (2013) also found that T2DM patients with HG have a mean LoS of 10.95 vs. 
8.31 days with no HG. Turchin et al. (2009) also reported that the LoS of diabetics who 
developed HG was 2.5 higher than those without HG (P < 0.0001). The duration of stay was 
found to be correlated with the severity of HG. Nirantharakumar et al. (2012) analyzed data from 
6,374 admissions between 2007–2010 in the UK and found that the adjusted LoS increased by 
2.33 times (95% CI 1.91–2.84) among the group with the most severe HG compared to 1.51 
(95% CI 1.35–1.68) among less severe HG. Therefore, a strong correlation was found between 
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LoS and mortality. Finally, the Turchin et al. (2009) study showed that each additional day with 
HG was associated with 85.3% more risk of inpatient mortality.  
2.6.1.2 Cost  
Research indicates that HG imposes a substantial economic burden on the healthcare 
system. However, estimating the exact magnitude of the expenses associated with HG care is a 
complex issue. This complexity is due to the wide variety of indirect costs related to each HG 
episode, such as comorbidities, adverse events, complications, and the long-term negative impact 
on quality of life and work productivity (Ahrén, 2013). Additionally, estimating the direct costs 
associated with HG is also not an easy task because each episode varies in its severity and the 
causes that lead to it (Liu, Zhao, Hempe, Fonseca, & Shi, 2012).  
Plenty of studies examined the economic impact of HG in diabetic patients in the U.S. 
Most of these studies focused on the costs associated with home medications, physician visits, 
and quality of life, according to a 2010 systematic review (Zhang et al., 2010). Curkendall et al. 
(2009) conducted a study on 70 hospitals and measured the costs associated with inpatient HG 
for T1DM and T2DM patients. They found that patients who develop HG incurred average 
charges of about $86,000 compared to $54,000 for those who did not have HG.  Their analysis 
concluded that HG was associated with 38.9% higher total charges (95% CI, 35.6%- 42.1%).  
Quilliam et al. (2011) investigated a large database from MarketScan® Research Databases from 
2004-2008 and found that HG represented 1% of all inpatient costs and 2.7% of ED costs. The 
average cost of HG admission was about $17,500, which is $4,000 higher than other diabetes-
related admissions, while ED visit average costs for HG were about $1,400 compared to $320 for 
other diabetes-related ED visits. 
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While there were big differences in the estimated costs found in the above studies, it is 
evident that the cost of HG-related admissions or ED visits were substantially higher among 
diabetics with HG than they were for those without. There were also some other studies in other 
countries such as Germany, U.K., and Sweden that estimated these costs (Zhang et al., 2010). 
Cost estimates were different from the U.S. because of the dissimilarities in the payment 
systems, care delivery, and extent of treatment (Liu et al., 2012). All in all, there is 
comprehensive agreement that hospital-related costs are substantially higher among HG patients. 
2.6.2 HG Outcomes (O) 
This study includes five outcome measures under the umbrella of (O). The first measure 
is mortality, which is the most commonly used measure for (O) among HG studies as well as 
studies that employed the BM for other diseases. Second is CV complications; they are found to 
be significantly associated with HG in numerous studies. Third is sepsis, which is a slightly less 
common outcome, but it is far-reaching and usually associated with higher levels of (U). The last 
two, patient falls and seizures, are less severe but more commonly found among HG patients. 
2.6.2.1 Mortality 
Diabetic patients who present to the ED with HG or develop in-hospital HG are 
considered at a higher risk of death. A recently published study examined the hospital discharge 
records of more than 5.4 million diabetic patients from 1997-2010 and found that those who 
developed HG in the hospital were 12% more likely to die in the hospital (OR 1.12, 95% CI 
1.09-1.15) (Gómez et al., 2015). Another study examined extensive data from 70 hospitals from 
2000-2006 and found the likelihood of dying among HG patients to be 7% higher (OR 1.07, 95% 
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CI 1.2-1.11) (Curkendall et al., 2009). However, the risk of mortality varied based on the 
severity of HG. Those with more severe HG were usually at a higher risk of mortality than were 
others with less severe HG. A retrospective cohort study analyzed 4,368 admissions between 
2003-2004 and found that the odds of inpatient death increased three times for every 10 mg/dl 
decrease in BG (Turchin et al., 2009).  
The relationship between in-hospital HG and mortality was also consistent with other 
studies conducted in other countries. In the UK, one study found that inpatient mortality was 5-
15% among patients with HG (Nirantharakumar et al., 2012) and another UK study found it to be 
7.6% (Brodovicz et al., 2013). In Spain, discharged patients’ records between 2005-2010 showed 
that 10.2% of those who develop inpatient HG died in the hospital compared to 9.5% without 
HG (OR 1.08, 95% CI 1.05-1.11) (Zapatero et al., 2014).  
2.6.2.2 Cardiovascular (CV) Complications 
HG steadily has been found to be a risk factor for developing a broad range of adverse 
CV complications in many systematic review studies (Goto et al., 2013; Yeh et al., 2015). These 
complications include MI, stroke, and arrhythmias (Johnston et al., 2011; Khunti et al., 2015). 
Another systematic review was conducted in 2013 to summarize the available data on the 
pathophysiology behind HG and CV complications (Hanefeld, Duetting, & Bramlage, 2013). It 
found that HG lead to CV complications by elevating the thrombotic tendency, affecting cardiac 
repolarization, provoking inflammation, and accelerating the process of development of 
atherosclerosis.  
A 2013 systematic review and meta-analysis found that SH was strongly associated with 
higher odds of developing CV diseases (RR 2.05, 95% CI 1.74 to 2.42) (Goto et al., 2013). Hsu 
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et al. found that stroke was a common comorbidity that independently associated with HG (OR 
2.84, 95% CI 2.31–3.48) followed by heart failure (HF) (OR 2.04, 95% CI 1.65–2.51) (Hsu et 
al., 2013). Simeone and Quilliam (2012) found that ED-treated HG cases usually had HF (OR 
1.70, 95% CI 1.49-1.93), peripheral vascular disease (OR 1.80, 95% CI 1.60-2.02), arrhythmia 
(OR 1.22, 95% CI 1.04-1.44), and stroke (OR 1.81, 95% CI 1.41-2.32). In another study, 
Quilliam et al. (2011) found various CV complications that were independently associated with 
inpatient HG. For example, theu study found that arrhythmia is higher among HG patients (OR 
1.69, 95%CI 1.17–2.44), coronary artery disease (CAD) (OR 1.48, 95%CI 1.21–1.81), HF (OR 
2.33, 95%CI 1.72–3.15), and stroke (OR 2.78, 95%CI 1.62–4.77) (Quilliam et al., 2011). 
Hospital admissions were common among HG patients with CV complications as well. When 
comparing patients without HG with those having HG, Hsu et al. (2013) found a higher 
hospitalization rate per 1,000 person-years for stroke (27.97 vs. 69.05), HF (27.96 vs. 65.51) and 
other CV diseases (106.00 vs. 323.36). 
2.6.2.3 Sepsis 
Sepsis is one of the most common unpleasant in-hospital complications among HG 
patients. A retrospective chart review of adult patients showed that the prevalence of sepsis was 
higher among those who developed HG than it was for those without HG (Blosch et al., 2010). 
Another retrospective cohort study of data from 70 hospitals also showed that diabetics who 
present to the hospital with HG had higher odds of developing sepsis (OR 6.9, 95% CI 6.3-7.4) 
than other diabetics without HG had(OR 2.2, 95% CI 2.1-2.3) (Curkendall et al., 2009). Besides 
sepsis at presentation, a study on over 5,000 diabetic patients admitted in 2010 found that the 
odds ratio of developing in-hospital sepsis among HG patients was 2.64 (95% CI 1.6-4.35) 
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(Dendy et al., 2014). Dendy et al. (2014) noted that the risk of developing septicemias among 
HG patients increased with the severity of HG, and found that the SH group had statistically 
higher proportions of sepsis (49.4%) compared to non-SH (12.5%). Abdelhafiz et al. (2012) 
found that sepsis was more likely to be found among HG patients than others with no HG (18% 
vs. 1.8%, P < 0.001). 
2.6.2.4  Patient falls 
In general, falls are undesired because they usually lead to fractures, hospital admissions, 
longer LoS, more utilization of healthcare resources, higher costs, and sometimes deaths 
(Chevalier et al., 2016). HG is one of the major factors that leads to patient falls at their homes. It 
has been estimated that HG events increase the odds of falls-related fractures by 70% (OR 1.7, 
CI 95% 1.58–1.83) (Johnston et al., 2012). Among hospitalized patients, falls and fall-related 
fractures are not uncommon among HG patients. One study in Australia included over 11,000 
patients between 1996-1998 and showed that patient falls occurred at a rate of 291.2 per 100,000 
people per year (Kennedy, Chapman, Nayar, Grant, & Morris, 2002; Malabu et al., 2014). 
Another Belgian study estimated that accidental falls were reported in 11.2% of the HG-related 
hospitalizations (Chevalier et al., 2016). A study included a large U.S. database from 1998–2010 
of non-insulin treated T2DM and found that HG increased the hazards of falls by 17% among 
hospitalized patients younger than 65 years (HR 1.17, 95% CI 0.88, 1.57), and 36% for those 
older than 65 years (HR 1.36, 95% CI 1.13–1.6) (Signorovitch et al., 2013). Kachroo et al. 
(2015) also found that elderly patients were usually found to have twice the risk for falls than 
younger patients were.  
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2.6.2.5 Seizures 
Seizures that are due to hypoglycemia are one of the unpleasant neurological 
complications of HG because they sometimes lead to permanent neuronal damage or even death 
(Stafstrom, 2008). A retrospective cohort study of data from 70 hospitals found that diabetics 
who presented to the hospital with HG had higher odds of developing seizures (OR 3.0, 95% CI 
2.7-3.4) than did other diabetics without HG (OR 2.2, 95% CI 2.1-2.2) (Curkendall et al., 2009). 
Holstein, Hammer, and Egberts (2003) estimated that 5% of HG cases presented to the ED had 
seizures. Another prospective, population-based study over four years in Germany revealed that 
about 7% of hospitalized diabetic patients with HG had seizures (Holstein & Egberts, 2001).  
2.7 Summary of Gaps in the Literature 
While plenty of studies examined different aspects of the HG problem such as risk 
factors, utilizations, or outcomes, this literature review revealed that most of these studies were 
not based on a logically-constructed theoretical framework. This resulted in segregated findings 
of some risk factors and some other information about the level of utilization or outcomes. In 
addition, SEM was not employed; hence, these studies did not demonstrate the presence of any 
interaction effects among different predictors. Moreover, the presence or absence of indirect 
effects among the factors has never been examined without SEM. Therefore, there is a need to 
conduct rigorous studies that include multiple risk factors of HG and examine their impact on 
hospital utilization and outcomes. One way is to employ the BM with SEM to be able to 
delineate differential effects of risk factors on utilization and outcome, coupled with the 
examination of the presence of any interaction effects among predictor variables.  
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CHAPTER 3 : METHODOLOGY 
3.1 Introduction 
This chapter presents the methodology applied to this study. The research questions are 
introduced, followed by the research design, data sources, sample, and subject of the study. Next, 
all study variables are described with their definitions and measurements. Afterward, sample size 
justification and power analysis are described. Last, details about the process of multivariate 
statistical analysis methodology are explained followed by the DTREG analysis. 
3.2 Research Questions 
As mentioned earlier, the main goal of this study is to identify the relative importance of 
factors related to HG utilization and outcomes among diabetic patients. In addition, the study 
explores the magnitude of the effects of each of the independent variables and whether there are 
any interaction effects among them. Therefore, the research questions for this study will be:  
RQ1. Which component is most important in determining the LoS among patients who 
develop HG, when other factors are held constant?  
RQ2. Which component is most important in determining the total cost among patients who 
develop HG, when other factors are held constant?  
RQ3. Which component is most important in determining the outcome among patients who 
develop HG, when other factors are held constant?  
RQ4. Is the need-for-care the most important predictor of use, while the effects of other 
predictors are simultaneously considered?  
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RQ5. Do the predictor variables (P, E, and N) show any significant interaction effects on 
utilization and outcomes? 
3.3 Research Design 
A quantitative, non-experimental and retrospective design was employed in this study by 
utilizing data from a national database for the years of 2012, 2013, and 2014. Although this 
observational study is non-experimental, it is more feasible, especially because of the availability 
of the comprehensive national database. Another issue is that the lack of previous studies 
examined HG under the guidance of the BM stimulate the need for such a study to help other 
researchers when formulating any future studies related to HG risk factors, utilization, and 
outcome.  
3.4 Data source and sample  
The retrospective design of the study was based on the selection of the study subjects 
from the Healthcare Cost and Utilization Project (HCUP) National database. HCUP is a group of 
healthcare databases sponsored by the Agency for Healthcare Research and Quality (AHRQ). 
HCUP databases aggregates all different data collection efforts of State data organizations, 
hospital associations, private data organizations, and the Federal government to establish a 
unified national information resource of encounter-level health care data (HCUP-us.ahrq.gov, 
2016). Since 1988, data is gathered every year from 47 States and the District of Columbia, 
representing 97% of all inpatient hospital discharges. AHRQ converts administrative health care 
data that were acquired from HCUP Partners into uniform databases that are easy to use by 
researchers. 
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The data for this study was extracted from the National Inpatient Sample (NIS), which is 
part of a family of databases drawn from all different State inpatient databases in HCUP. A 20% 
stratified sample of all discharges from community hospitals, not including rehabilitation or 
long-term acute care hospitals, is approximated by the NIS (AHRQ.gov, 2016). The data 
includes all patients, regardless of payer, including individuals covered by Medicaid, Medicare, 
private insurance, or uninsured. Nis is considered the largest all-payer inpatient care database in 
the U.S. as it contains data from more than seven million hospital stays each year (AHRQ.gov, 
2016).  
This study included all cases presented to the ED in the years 2012, 2013, and 2104. 
Based on the International Classification of Diseases Ninth Revision (ICD-9) diagnostic codes, 
only adults 18 and older, who were diagnosed with T1DM or T2DM and were diagnosed with 
HG were included in the study.   
3.5 Subjects for the Study 
The unit of analysis of this study is individual patients. Data on patients who presented to 
the ED between January 1, 2012 and December 31, 2014, with the diagnosis of T1DM or T2DM, 
were included. Therefore, inclusion criteria for patients was: 
C1: Age > or = 18 
C2: Presented to ED between January 1, 2012 and December 31, 2014 
C3: Diagnosed with diabetes 
C4: Admitted with or developed HG during hospitalization 
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Because of the nature of the study, non-diabetics and diabetics without HG were 
excluded from the study. Patients who were younger than 18 years were also excluded because 
genetic diseases are the predominant factors leading to HG among children (Wang, Shandro, 
Sohoni, & Fassl, 2011). In addition, factors that lead to HG are different between newborns, 
infants, toddlers, and older children (Brook, Clayton, & Brown, 2010). Last, when compared to 
non-pregnant adults, HG during pregnancy has different maternal risk factors, different 
pregnancy outcomes, and a wide-range of fetal-related complications (Naik et al., 2016; 
Ringholm, Pedersen-Bjergaard, Thorsteinsson, Damm, & Mathiesen, 2012; Wallis, 2008). 
Therefore, all pregnant women were excluded from this study. 
3.6 Study Variables  
The BM is the principal framework for this study. Different indicators or variables were 
considered under each of the main three constructs/components: P, E, and N. In addition, the 
study also included other indicators under the utilization and outcome constructs. The following 
table summarizes the study variables:   
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Table 2. Operational Definition and Measurement Instruments for Study Variables 
  Variable name 
Variable 
type 
Definition Scale 
Predisposing component (P) 
1 Age Exogenous 
Age of the patient. All adults 
18 years and above 
Continuous in years 
2 Gender Exogenous Male or Female Categorical (Dichotomous) Male=0, Female=1 
3 AA_Hisp Exogenous 
The ethnicity of the patient. 
Whether patient’s ethnicity is 
African American or Hispanic 
or not 
Categorical (Dichotomous). 1= African American or 
Hispanic, 0=Others 
4 Dementia Exogenous Patient has dementia or not Categorical (Dichotomous) No dementia=0, Yes=1 
5 No Depression Exogenous Patient has no depression 
Categorical (Dichotomous) No b depression=1, 
Depression=0 
6 
Healthy lifestyle 
(HLS) 
Exogenous 
Refer to the healthy lifestyle 
for the patient, which is 
tobacco-free, alcohol-free, 
and no drug abuse 
Categorical 2=Patient has a healthy lifestyle with no 
smoking, no alcohol, and no drugs. 1= Patient does one of 
the above, 0= Patient does 2 or more of the above. 
Enabling component (E) 
1 Medicaid Exogenous 
Whether the patient is covered 
by Medicaid or not 
Categorical (Dichotomous): Medicaid=1, Others (Medicare, 
Private, no insurance)=0 
2 SES Exogenous 
The socio-economic status of 
the patient based on the 
median household income for 
patient 
Categorical: 1= 0-25th percentile, 2= 26th to 50th 
percentile, 3= 51st to 75th percentile, 4= 76th to 100th 
percentile 
3 Urban_hosp Exogenous 
Hospital located in an Urban 
or rural area 
Categorical (Dichotomous). Urban=1, Rural=0 
4 Patient Location Exogenous 
Patient home location. Based 
on the location's county 
population. 
Categorical: 1= Not metropolitan or micropolitan county, 2= 
Micropolitan county, 3=  Counties in metro areas of 50,000-
249,999 population, 4=  Counties in metro areas of 250,000-
999,999 population, 5= Counties of metro areas of >=1 
million population 
Need-for-Care component (N) 
1 
DM 
Complications 
Exogenous 
Patient has any DM specific 
complication (eye, 
neurological, cardiac, renal, 
others) 
Categorical (Dichotomous). No complications=0, Yes=1 
2 Uncontrolled DM Exogenous 
Patient has DM that is 
uncontrolled 
Categorical (Dichotomous). No=0, Yes=1 
3 DMII Exogenous Patient is T2DM Categorical (Dichotomous). T2DM=1, T1DM=0 
4 
BMI 
underweight 
Exogenous 
Patient BMI category is 
underweight 
Categorical (Dichotomous). No=0, Yes=1 
5 Hypertension Exogenous Patient has hypertension Categorical (Dichotomous). No=0, Yes=1 
6 Hyperlipidemia Exogenous Patient has hyperlipidemia Categorical (Dichotomous). No=0, Yes=1 
7 Liver_dis Exogenous 
Patient has moderate to severe 
liver disease 
Categorical (Dichotomous). No=0, Yes=1 
8 Renal_disease Exogenous Patient has Renal disease Categorical (Dichotomous). No=0, Yes=1 
9 Cancer Exogenous Patient has malignancy Categorical (Dichotomous). No=0, Yes=1 
10 
Charlson 
Comorbidity 
Index (CCI) 
Control Score of the CCI Categorical. Scores 1-25 
Utilization (U) 
1 Hospital LoS Endogenous Patient days in the hospital Continuous: in days 
2 Cost Endogenous 
Total charges in USD for the 
admission 
Continuous: in USD 
Outcome (O) 
1 Outcome Endogenous 
The severity level of the 
outcome ranging from no 
adverse outcomes to death 
Categorical: 3= patient died in hospital, 2= patient 
developed CV complications and/or sepsis, 1= patient had 
seizures and/or fall, 0= none of the above 
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3.6.1 Predisposing component (P): 
As mentioned earlier, the study includes the main key variables used in previous studies 
that were found to be relevant risk factors related to HG among diabetic patients. Regarding the 
predisposing component or risk propensity profile, age, ethnicity, gender, dementia, depression, 
and healthy life status were considered as indicators in this study. The age of the patients was 
collected in years. Gender was either male or female. Ethnicity was either African American, 
Hispanic, or others. These categorizations were based on evidence from the literature review that 
showed that African Americans and Hispanics had higher odds of developing HG when 
compared to others. Regarding healthy life status, patients were categorized into three groups: 
those who do not drink, smoke, or abuse drugs; those who do one of these; and those who do two 
or more. 
3.6.2 Enabling component: 
The study included the four major indicators for the enabling construct, which were 
frequently used in previous studies to facilitate or impede the use of health services: medical 
insurance type, SES level, the location of the patient, and the hospital location. Health insurance 
was categorized into two groups: those who were on Medicaid and those who had either 
Medicaid, private insurance, or no insurance. This categorization is relevant to this study as 
Medicaid patients found to be the sickest group when compared to the other groups (Adelmann, 
2003). Regarding SES, the categorization was based on the median household income for the 
patient. Of the four categories that represent income percentile level, category one represented 
the poorest from the 0-25th percentile, while category four represented the richest from the 75th to 
100th percentile. Hospital locations were categorized into urban or rural. Lastly, patient locations 
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were categorized into five groups based on the population density of the county related to 
patients’ homes: the smaller the category number, the smaller the county population size. 
3.6.3 Need-for-Care (N): 
Based on the review of the literature, the indicators for N were the DMII, the presence of 
diabetes-related complications (DM_complications), uncontrolled diabetes (uncontrolled_DM), 
underweight (BMI underweight), hypertension, hyperlipidemia, liver disease (liver_dis), renal 
disease (renal_disease), and cancer. All of these variables are dichotomous in nature, No=0 while 
Yes=1. These variables were extracted from the ICD-9 codes associated with each case in the 
database (Appendix I, Table 26).  
As discussed earlier, CCI was found to have a broad range of consequences in addition to 
HG, which included CV complications, falls, higher costs, longer LoS, and more risks to 
mortality. Therefore, it was more appropriate for this study to consider CCI as a control variable. 
It is also worth mentioning that this approach of controlling CCI was employed among numerous 
previous studies that examined risk factors for HG among diabetic patients (Fayfman et al., 
2016; Khunti et al., 2015; Moen et al., 2009; Nirantharakumar et al., 2012; Patel et al., 2015; 
Zapatero et al., 2014). 
3.6.4 Utilization (U) 
As discussed earlier, the two indicators examined in this study for U are LoS and the total 
cost. LoS is the duration patients spent in the hospital in days. Total cost refers to the total cost of 
care in U.S. dollars. The number of hospital days does not necessarily correlate with the total 
cost of the hospital stay. In addition, some variables might influence LoS or the total charges 
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without affecting the other variables. Therefore, the study treated the two utilization variables 
separately. 
3.6.5 Outcome (O) 
To facilitate data analysis and interpretations, the outcome variable was coded as a 
categorical variable from 0-3 depending on the severity. Category 3 is the most adverse outcome 
that refers to a patient’s death in the hospital. Category 2 is when the patient did not die but 
experienced severe adverse outcomes including sepsis and/or CV complications such as MI, HF, 
stroke, or arrhythmias. Category 1 includes minor adverse outcomes: seizures and/or falls. 
Lastly, category 0 represents patients discharged from the hospital without any of the previous 
complications. Thus, the higher the outcome index, the poorer the health outcome observed. 
3.7 Power Analysis and Sample Size Justification  
Statistical power indicates the odds of observing a treatment effect when it occurs. Power 
analysis helped in determining the appropriate sample size by taking the alpha size, beta size, 
standard deviation, and mean. Power analysis was conducted before the study to help determine 
the sample size needed, and again at the end of the study to make sure that the included sample 
size was appropriate. The higher the power, the more trustworthy the results and applicable to 
the population. However, it is necessary to note that statistical significance in hypothesis testing 
is associated with the sample size. Power analysis calculation is as follows: 
1. Power =1-beta (type II error) 
 
2. Effect size = signal (program effect) / noise (error) 
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Effect size (ES) is a name given to a family of indices that measure the magnitude of a 
treatment effect: 0.1 is minimal, 0.3 is optimistic. 
Power analysis also helped avoid making a Type I or Type II error. Type I error occurs 
when incorrectly rejecting a true null hypothesis and concluding that a statistically significant 
relationship exists when it does not. Therefore, the level of significance (alpha) is set at the 0.05 
level to minimize the chance of Type I error. Type II error occurs when failing to reject a false 
null hypothesis and concludes that no significant relationship exists when it does. To minimize 
this risk, the beta value was set at 0.8 or higher. 
3.8 Statistical Analysis 
Initially, descriptive statistics of the data were determined using the SPSS software. 
General characteristics of the data were inspected as well as the presence of any missing results. 
Then, SPSS was used to look for multicollinearity or correlations among different variables for 
each construct. Highly correlated variables (>0.9) were not accepted in the model because of the 
multi-collinearity problem. 
3.8.1 Structural Equation Modeling (SEM) 
SEM was used as the main multivariate statistical method for the analysis. This is 
because SEM is a very versatile method that allows for the examination of latent constructs with 
multiple indicators; accounts for measurement errors; and conducts Confirmatory Factor 
Analysis (CFA). Moreover, because this study employs the BM, multiple hypotheses needed to 
be examined, and SEM effectively served this purpose. Another advantage of SEM is that it can 
establish causal sequence and confirm the stability of the measurement model over time. 
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Path analysis differs from the traditional regression analysis in certain ways. Regression 
analysis, or covariance analysis, is a multivariate analysis methodology that is used to capture 
multiple relationships while simultaneously providing a simple and fast estimation result (Ahn, 
2002). Path analysis, on the other hand, is a complementary methodology to regression analysis 
that uses a structural equation model to specify relationships among a set of variables, through 
path diagrams showing a system of simultaneous equations (Land, 1969; Petraitis, Dunham, & 
Niewiarowski, 1996). 
While path analysis is an extension of regression, its principal advantage is the 
simplification of complex relationships among the study variables through the visualization of 
relationships between study variables using a path diagram (Lleras, 2005; Wan & Cooper, 1988). 
Moreover, path analysis does not show only direct relationships, as regression analysis does, but 
also, path analysis traces out indirect relationships, a step which is a key feature of the path 
analysis (Wan, 2002). Also, it is not possible to specify mediating variables in one regression 
analysis, but it is possible with path analysis (Streiner, 2005). However, it should be understood 
that path analysis cannot confirm causation between variables (Lleras, 2005; Petraitis et al., 
1996; Wan, 2002). 
For this study, the IBM® SPSS® Amos Graphics 22 software was used to construct the 
measurement models. Then, CFA was conducted to test the construct validity of the 
measurement models and make any modifications based on the results. Lastly, a structural 
equation model was performed, based on the BM, and then analyzed by the goodness of fit 
statistics of the model. 
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3.8.2 Confirmatory Factor Analysis (CFA) 
Confirmatory Factor Analysis (CFA) is a statistical methodology that was developed to 
facilitate the evaluation of the validity of the latent constructs’ measurement models (Byrne, 
2001). Thus, it was used to examine whether the number of factors and loading of the measured 
(indicator) variables on them complies with the expected, which is originally based on a 
theoretical background (Albright & Park, 2009). Hence, CFA helped in examining whether the 
measures of a construct were consistent with the model proposed. 
One of the strengths of CFA is that when it is paired with a strong theoretical foundation 
prior to analyzing data, it can provide a power causal inference model by its ability to test the 
hypothesis indicated in the study. In addition, CFA allows the researcher to impose constraints 
on the model to determine specific correlations among different variables (Wan, 2002). 
However, if the assumptions of the model are violated, the results have a tendency to be biased 
or can lead to drawing a wrong conclusion. Therefore, the validity and reliability of the 
measurement model need to be carefully examined before conducting SEM.  
 
The three assumptions of CFA are: latent and observable variables are measured as 
deviations from their means, observable variables in the indicators are more prevalent than the 
unobservable ones, and the different factors are not correlated (Wan, 2002). Therefore, 
correlation analysis was also performed prior to CFA. Afterward, CFA was used to validate each 
of the three measurement models, (P, E, and N) by examining the relationships between the 
latent constructs and their indicators. This sequence identified whether the number of factors and 
loadings of the measured variables conformed to what was expected by the pre-established 
theory of this study. 
62 
3.9 Measurement Models 
Measurement models illustrate the relationships between latent constructs and their 
indicators. The first component is the predisposing component or risk propensity profile (a latent 
exogenous variable). As a latent construct, risk indicators including age, gender, ethnicity, 
depression, dementia, and healthy lifestyle (HLS) were coded consistently in the same direction. 
Factors with higher scores were considered to have an increased in the risk propensity. 
 
Figure 4. Measurement Model for the Predisposing Component (Risk Propensity as an 
Exogenous Latent Variable) 
 
Next is the enabling latent construct, which includes four indicators as shown in the 
following illustration: 
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Figure 5. Measurement Model for the Enabling Component (Exogenous Latent Variable) 
 
N is assumed to be affected by P or E, and therefore, N was categorized as an 
endogenous variable. The following diagram shows the measurement model for N:  
 
Figure 6.  Measurement Model of the Need-for-Care Component (Need-for-care as an 
Exogenous Latent Variable) 
64 
3.10 Structural Equation Model with the Measurement Models 
SEM is a statistical analysis process utilizing a linear variance-covariance matrix to 
analyze latent variables (both exogenous and endogenous) using factor loading, and thereby 
making it a subtype of CFA (Preacher, Cai, & MacCallum, 2007). The model overcomes 
weaknesses of factor analysis and structural equation modeling by merging them into a single 
model that estimates both latent variables and structural relations among the latent variable 
(Wan, 2002). Another strength of SEM is that it allows for a direct test of the theory in terms of 
how well the model determines data (Byrne, 2001). The path diagram produced by SEM 
simplifies the relationship among all different variables (Bentler & Bonett, 1980; Schoenberg, 
1989). Therefore, SEM is useful for this study as it contained a large number of the study 
variables with hypothesized causal links. 
Based on the BM, two models were proposed. In the first model, U, an endogenous 
variable, is represented by LoS: 
 
Figure 7.  Andersen Behavior Model of Healthcare Utilization: Predictors of Hypoglycemia 
LoS and Outcome - Simplified 
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As is shown in the above figure, P and E are correlated with N. Also, all three 
components (P, E, and N) have a direct impact on LoS as well as on O. In addition, LoS is 
considered to have a direct impact on O. CCI is a control variable that is correlated with N. This 
configuration was constructed based on the findings of previous studies of HG that show how 
different factors that were inter-related with each other impacted the level of utilization and 
outcome among HG patients. For example, different studies that were discussed in the previous 
chapter show the relationship between age, severity of HG, LoS, total cost, and outcome. Also, 
some other studies showed the inter-relation between SES, medication adherence, severity and 
frequency of HG, LoS, total cost, and outcome. Therefore, the above model was formulated to 
examine the inter-relations between P and E on N. 
When considering that total charges represent U, a similar model was constructed:   
 
Figure 8. Andersen Behavior Model of Healthcare Utilization: Predictors of Hypoglycemia 
Total Charges and Outcome - Simplified 
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3.11 Validation of the Models 
The above models were validated through the following statistics: 
1. Factor loadings (standardized regression coefficient) 
2. Goodness-of-fit statistics 
3. Modification indices between errors 
The model validation process included validating each measurement model developed, 
followed by a causal model in the SEM to determine the integrity of the proposed causal model. 
3.11.1 Factor loadings (standardized regression coefficient) 
Factor loadings with critical ratio value (equal to +1.96 or higher, and -1.96 or lower) 
were considered statistically significant at 0.05 level (Byrne, 2001). Indicators with insignificant 
values were excluded. Additionally, indicators with very low standardized regression coefficients 
might also be excluded from the original model to generate a more fit model. 
3.11.2 Goodness-of-fit statistics 
Goodness-of-fit statistics were produced by the AMOS software to help identify whether 
the measurement models fit the data (Bentler & Bonett, 1980). Therefore, the overall model fit 
was evaluated to understand how well the models fit the data. Consequently, goodness-of-fit 
statistics facilitated the decision to accept the SEM or not. The total number of known variances 
and covariances were compared to the estimated elements or parameters in the available sample 
(Bentler, 1990). The target was to have an over-identified model (with a surplus of information 
or degrees of freedom). Chi-square value was used to show whether the model was reasonably 
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fitted to the data. In the case of a just-identified model, df should be equal to 0. If the model did 
not fit well with the data based on the selected goodness-of-fit statistics, the model was revised. 
In order to improve the new revised model, first, insignificant factor loadings were eliminated.  If 
removing insignificant factor loadings did not prove the researcher’s acceptable goodness-of-fit 
statistics, then measurement errors of factor loadings would be correlated with each other to get a 
better fit looking at the modification index (MI).  
The following indicators (Table 3) were considered in the study to determine the 
construct validity of each measurement model: 
Table 3.  Goodness-of-Fit Indices and Criteria for Model Validation 
Index Criterion Definition 
Chi-square (x²)  
 
The discrepancy should 
be minimal (<5) 
 
evaluates the degree of discrepancy between the sample and 
fitted covariances (Hooper, Coughlan, & Mullen, 2008; Hu & 
Bentler, 1999) 
Degrees of Freedom (df)  
 
greater than or equal to 0  
 
The difference between the number of parameters to be estimated 
from the number of known elements (correlations) in the 
correlation matrix (Weston & Gore, 2006) 
Likelihood Ratio (x²/df)  
 
smaller than 5.0 suggests 
a good fit  
 
Tests the null hypothesis that the sample is obtained from a 
population with characteristics of the covariance matrix (Wan, 
2002) 
 
GFI (goodness-of-fit index) 
 
0–1 (the larger, the 
better) 
>0.9 
 
Summarize the variance explained for the entire model (Weston 
& Gore, 2006) 
 
AGFI (adjusted goodness-
of-fit index) 
 
0–1 (the larger, the 
better) 
>0.9 
 
Measures GFI while considering the degrees of freedom 
available 
 
Root Mean Squared Error 
of Approximation 
(RMSEA)  
 
smaller than 0.09 
suggests a good fit  
 
Assesses the degree of model adequacy on the basis of 
population discrepancy (Wan, 2002) 
 
Comparative Fit Index 
(CFI)  
 
>0.90 suggest a good fit  
 
Evaluates the model by comparing the χ2 the model to the null 
model, while taking into account the sample size (Hooper et al., 
2008) 
 
Tucker Lewis Index (TLI)  
 
>0.90 suggest a good fit  
 
also known as NNFI, compares the discrepancy between the χ2 
of the hypothesized model to the one in the null model (Hu & 
Bentler, 1999) 
Hoelter's Critical N (CN)  
 
= or > 200 
 
Specifies the largest sample size to be accepted (Hoelter, 1983) 
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3.11.3 Modification indices between errors 
To improve the model fit, modification indices were examined. The pairs of error terms 
with high modification indices were correlated to each other in an effort to reduce the chi-square 
and to improve the model fit. 
3.12 Decision Tree Regression (DTREG) 
Decision Tree Regression is a robust application that is usually used for data mining, 
which is a process of extracting relevant information from the database, to generate user-friendly 
and easy-to-interpret models such as the decision tree model (dtreg.com, 2017). The software 
generates a series of branched “nodes” that describe the relationship between variables in the 
data. Examining the values in terminal nodes, which enclose the value of the predictor 
(independent) variables, allowed predicting the value of the target (dependent) variable (Sherrod, 
2014). Therefore, DTREG modeling was conducted following path analysis to further examine 
the probability of the different target variables included in this study. 
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CHAPTER 4 : RESULTS 
4.1 Introduction 
This chapter includes the results of the data analysis. Results of descriptive statistics and 
correlation analysis of all variables used in this study, generated by the SPSS statistical software 
program, are shown first. Then, CFA results for all the three latent constructs: (P, E, and N), are 
presented. It includes the results of the generic models followed by the modified models. Next, 
the two generated structural equation models with the measurement models for LoS and total 
charge are presented. Afterward, results of the DTREG analysis for the three target variables: 
LoS, total charge, and O are shown, including a decision tree model for each of them. Last, each 
of the five hypotheses of the study were examined. 
4.2 Descriptive Statistics 
After merging the databases for the three years, cases involving patients that were 
younger than 18 years were excluded. Afterwards, all cases that included pregnant women were 
also excluded. Then, only cases that were admitted through ED, diagnosed with T1DM or 
T2DM, and presence of HG were selected. When examining the selected cases, only a few 
variables (sex, AA_Hisp, patient_loc, Medicaid, and SES) had missing data, and the missing data 
for each of the variables constituted less than 5%. Therefore, missing data was replaced by the 
calculated mean. When checking for normality, there were few outliers among the two variables: 
LoS and total charge, and these outliers were less than 0.3% of the data. Therefore, these outliers 
were excluded from the analysis in order to have normally distributed data. The following table 
shows the descriptive statistics of the variables after cleaning the data: 
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Table 4.  Descriptive Statistics  
  
Vali
d 
Miss
ing 
Mean 
Std. 
Deviat
ion 
Skew
ness 
Kurto
sis 
Range Min. Max. Sum 
Age 4,822 0 58.42 17.08 -0.22 -0.64 72 18 90 281,700 
Sex 4,822 0 0.48 0.50 0.08 -1.99 1 0 1 2,317 
AA_Hisp 4,822 0 0.32 0.47 0.78 -1.40 1 0 1 1,540 
Dementia 4,822 0 0.08 0.27 2.94 7.88 1 0 1 377 
No_ 
Depression 
4,822 0 0.61 0.49 -0.44 -1.81 
1 0 1 
2,928 
HLS 4,822 0 1.57 0.68 -1.31 0.34 2 0 2 7,592 
Urban_ 
hosp 
4,822 0 0.77 0.42 -1.30 -0.31 
1 0 1 
3,726 
Patient_ 
Loc 
4,822 0 4.18 1.16 -1.30 0.59 
4 1 5 
20,140 
SES 4,822 0 2.21 1.07 0.36 -1.14 3 1 4 10,678 
Medicaid 4,822 0 0.19 0.39 1.57 0.46 1 0 1 924 
CCI 4,822 0 2.43 2.43 1.36 2.22 16 0 16 11,715 
DM_ comp 4,822 0 0.23 0.42 1.28 -0.37 1 0 1 1,113 
Uncont DM 4,822 0 0.24 0.42 1.24 -0.45 1 0 1 1,138 
DMII 4,822 0 0.85 0.35 -2.01 2.04 1 0 1 4,120 
Under_ Wt 4,822 0 0.14 0.34 3.84 8.53 1 0 1 476 
Hyper- 
lipidemia 
4,822 0 0.40 0.49 0.39 -1.85 
1 0 1 
1,947 
Renal_ 
Disease 
4,822 0 0.29 0.45 0.95 -1.10 
1 0 1 
1,380 
Liver_ dis 4,822 0 0.06 0.23 3.82 12.61 1 0 1 275 
Hyper- 
tension 
4,822 0 0.76 0.43 -1.24 -0.47 
1 0 1 
3,679 
Cancer 4,822 0 0.08 0.27 3.13 7.82 1 0 1 379 
LoS 4,822 0 3.59 3.56 2.71 9.97 27 0 27 17,287 
TOTCHG 
4,822 0 
27,30
5 
27,381 2.75 9.86 
205,78
6 1713 
207,49
9 
131,662,57
9 
Outcome 4,822 0 0.90 0.98 0.30 -1.70 3 0 3 4,336 
YEAR 4,822 0 2,013 0.82 0.00 -1.50 2 2012 2014 9,706,689 
 
As is shown in the above table, the total sample size was 4,822 with no missing data. A 
sample size of 4,822 participants seems sufficient as the general guidelines for SEM sufficient 
sample indicate 10 to 20 participants per estimated parameter (Weston & Gore, 2006). To 
examine normality, the skewness and kurtosis indices for each variable were inspected to 
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determine its normality (Weston & Gore, 2006). Extreme values were considered when the 
absolute values for skewness are >3.0, and >10.0 for kurtosis (Kline, 2005; Weston & Gore, 
2006). In examining the results, it seems that the skewness and kurtosis indices for all variables 
were within the recommended range, except for the three variables: under_wt, liver_dis, and 
cancer, where the values were above the suggested range. Appendix D also shows histograms for 
all of the variables, and Appendix C demonstrates the frequency of the data. Again, frequency 
analysis showed that those three variables: under_wt, liver_dis, and cancer had very skewed 
distributions, about 10% with a value =1 vs. 90% =0. Therefore, these variables were excluded 
from the models. 
4.3 Correlation Analysis 
Since most of the variables in the data were categorical in nature, the Spearman's rank-
order correlation was used to examine the correlation among the variables (Hauke & Kossowski, 
2011). The relationship between two variables was expressed as a range between -1 to +1. 
Correlation coefficients that are >0.85 are considered to be strong positive relationships and <-
0.8 are regarded as a strong negative correlation between two variables and may indicate 
potential problems (Kline, 2005; Weston & Gore, 2006). As is shown in the correlation tables in 
Appendix E, none of the variables was highly correlated with the other, and therefore all 
variables were considered in the models. 
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4.4  Confirmatory Factor Analysis (CFA) 
This study has three latent variables: P, E, and N and all are exogenous variables. A 
separate measurement model was developed for each of the latent variables and then 
independently validated by CFA. 
4.4.1 The Predisposing component (P) or Risk Propensity 
As mentioned earlier, the P construct was composed of six indicators: age, sex, AA_Hisp, 
dementia, depression, and HLS. Using AMOS Graphics 23, a CFA model was formulated:  
 
Figure 9. Measurement Model for the Predisposing Component (An Exogenous Latent 
Variable) - Generic 
 
As depicted in Figure 9, all indicators had a strong positive correlation with the latent 
variable P except for sex and AA_Hisp where the correlation was very weak. However, all 
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indicators for the construct were statistically significant at <.05 with critical values >1.96 except 
for sex, where P=0.81 and CR =0.24 (Table 5). Therefore, those two variables were excluded 
from the original model in the modified/nested model: 
 
Figure 10. Measurement Model for the Predisposing Component (An Exogenous Latent 
Variable) - Modified 
 
As is shown in the above-modified model for P, all indicators had a strong positive 
correlation with the latent variable P. In addition, there was a correlation between HLS and 
no_depression, which indicated an indirect effect on the latent variable P. As shown in the 
following table (Table 5), the modified model had all critical ratios >1.96 and they were 
statistically significant at p ≤ .05. 
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Table 5.  Parameter Estimates for the Predisposing Component Measurement Models 
 Generic Model Revised Model 
Indicator U.R.W S.R.W S.E C.R. P U.R.W S.R.W S.E C.R. P 
HLS < ---P 0.023 0.455 0.001 19.121 *** 0.015 0.368 0.001 11.42 
*
** 
No_Depressio
n < ---P 
0.016 0.457 0.001 19.159 *** 0.011 0.372 0.001 
11.44
2 
*
** 
Dementia < ---
P 
0.007 0.367 0 17.204 *** 0.005 0.329 0 
11.22
3 
*
** 
Age < ---P 1 0.798    1 0.965    
AA_Hisp < ---
P 
0.002 0.052 0.001 3.05 0.002 - - - - - 
Sex < ---P 0 0.004 0.001 0.24 0.81 - - - - - 
d4 < -- > d3      0.041 0.143 0.006 7.439 
*
** 
*** . Correlation is significant at the 0.05 level. 
Note: U. R.W. = Unstandardized Regression Weight; S. R. W. = Standardized Regression Weight; S. E. = Standard 
Error; C. R. = Critical Ratio 
 
The goodness-of-fit statistics were also significantly improved in the revised model as 
shown in the following table: 
Table 6.  Goodness-of-Fit Statistics of Generic and Revised Model for the Predisposing 
Component 
Fit Indices Criterion Generic Model Revised Model 
Chi-square (x²) < 5 341.5 1.45 
Degrees of freedom (df) ≥ 0 9 1 
Likelihood ratio (x²/df) <4 37.9 1.45 
Probability (p or p-close) ≥ .05 0 0.228 
Goodness-of-Fit Index (GFI) >.90 0.98 1 
Adjusted GFI (AGFI) >.90 0.95 0.99 
Tucker Lewis Index (TLI) >.90 0.75 0.99 
Comparative Fit Index (CFI) >.90 0.85 1 
Root Mean Square Error of Approximation (RMSEA) ≤.09 0.088 0.01 
Hoelter’s Critical N (CN) > 200 239 12747 
4.4.2 The Enabling component (E) 
The E construct was composed of 4 indicators: urban_hosp, patient_loc, SES, and 
Medicaid. Using AMOS Graphics 23, a CFA model was formulated: 
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Figure 11. Measurement Model for the Enabling Component (An Exogenous Latent Variable) 
- Generic 
 
As is shown, all indicators had a strong positive correlation with the latent variable E 
except for Medicaid, where the correlation was very weak and adverse. In addition, all indicators 
for the construct were statistically significant at <.05 with critical values >1.96 except for 
Medicaid, where P=0.171 (Table 7). Therefore, the variable “Medicaid” was excluded in the 
modified model: 
 
Figure 12. Measurement Model for the Enabling Component (An Exogenous Latent Variable) 
- Modified 
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The above modified model for E shows that all indicators had a strong positive 
correlation with the latent variable P. In addition, the modified model had all critical ratios >1.96 
and they were statistically significant at p ≤ .05.  
Table 7.  Parameter Estimates for the Enabling Component Measurement Models 
 Generic Model Revised/Nested Model 
Indicator U.R.W S.R.W S.E C.R. P U.R.W S.R.W S.E C.R. P 
SES 
< --- E 
0.251 0.244 0.058 4.349 *** 0.265 0.252 0.058 4.541 *** 
Patient_Loc 
< --- E 
1 0.903    1 0.88    
Urban_hosp 
< --- E 
0.099 0.247 0.023 4.352 *** 0.104 0.254 0.023 4.543 *** 
Medicaid 
< --- E 
-0.014 -0.029 0.008 -1.711 0.171 - - - - - 
*** . Correlation is significant at the 0.05 level. 
Note: U. R.W. = Unstandardized Regression Weight; S. R. W. = Standardized Regression Weight; S. E. = Standard 
Error; C. R. = Critical Ratio 
 
Because the model has only three variables, it was considered a “just identified model” 
(Table 8): 
Table 8.  Goodness-of-Fit Statistics of Generic and Revised Model for the Predisposing 
Component 
Fit Indices Criterion Generic Model Revised Model 
Chi-square (x²) < 5 1.75 - 
Degrees of freedom (df) ≥ 0 2 0 
Likelihood ratio (x²/df) <4 0.877 - 
Probability (p or p-close) ≥ .05 0.4 - 
Goodness-of-Fit Index (GFI) >.90 1 1 
Adjusted GFI (AGFI) >.90 0.99 - 
Tucker Lewis Index (TLI) >.90 1 - 
Comparative Fit Index (CFI) >.90 1 1 
Root Mean Square Error of Approximation 
(RMSEA) 
≤.09 0 0.08 
Hoelter’s Critical N (CN) > 200 16,477 - 
 
As is shown above, the RMSEA was 0.08, an acceptable model fit, for the revised model. 
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4.4.3 The Need-for-Care Component (N) 
As mentioned earlier, the N construct was composed of six indicators: DM_comp, DMII, 
renal_disease, hyperlipidemia, hypertension, and uncontrolled_DM. using AMOS Graphics 23, a 
CFA model was formulated:  
 
Figure 13. Measurement Model for the Need-for-Care Component (An Exogenous Latent 
Variable) - Generic 
 
As shown in Figure 13, all indicators had a strong positive correlation with the latent 
variable N except for uncontrolled_DM, where the correlation was negative. In addition, all 
indicators for the construct were statistically significant at <.05 with critical values >1.96 except 
for uncontrolled_DM, where P=0.09 (Table 9). Therefore, uncontrolled_DM was excluded in the 
modified model: 
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Figure 14. Measurement Model for the Need-for-Care Component (An Exogenous Latent 
Variable) – Modified 
As is shown, the above-modified model for N shows that all indicators had a strong 
positive correlation with the latent variable (N). In addition, some correlations between the 
indicators had been established to improve the model fit. As shown in the following table (Table 
9), the modified model had all critical ratios >1.96 or <-1.96 and they were statistically 
significant at p ≤ .05. 
Table 9.  Parameter Estimates for the Need-for-Care Component Measurement Models 
 Generic Model Revised Model 
Indicator U.R.W S.R.W S.E C.R. P U.R.W S.R.W S.E C.R. P 
DMII < --- N 0.453 0.317 0.029 
15
.6 
**
* 
0.813 0.518 0.061 13.281 *** 
DM_comp < --- N 0.265 0.155 0.033 
8.
1 
**
* 
0.298 0.159 0.053 5.657 *** 
Hyperlipidemia < --- N 1.051 0.529 0.048 
21
.7 
**
* 
0.485 0.222 0.041 11.959 *** 
Renal_Disease < --- N 1 0.514    1 0.497    
Hypertension < --- N 0.95 0.58    0.95 0.502    
UncontDM < --- N 
-
0.054 
-
0.031 
0.032 
-
1.6 
0.
09 
- - - - - 
n14 <--> n15      0.072 0.412 0.003 21.607 *** 
n11 <--> n12      -0.024 -0.19 0.003 -8.971 *** 
n11<--> n13      0.028 0.17 0.003 8.25 *** 
n12<--> n13      -0.023 -0.197 0.003 -8.262 *** 
*** . Correlation is significant at the 0.05 level. 
Note: U. R.W. = Unstandardized Regression Weight; S. R. W. = Standardized Regression Weight; S. E. = Standard 
Error; C. R. = Critical Ratio 
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The goodness-of-fit statistics were also significantly improved in the revised model as 
shown in Table 10: 
Table 10.  Goodness-of-Fit Statistics of Generic and Revised Need-for-Care Component 
Fit Indices Criterion Generic Model Revised Model 
Chi-square (x²) < 5 978 7.14 
Degrees of freedom (df) ≥ 0 10 2 
Likelihood ratio (x²/df) <4 97.8 3.57 
Probability (p or p-close) ≥ .05 0 0.02 
Goodness-of-Fit Index (GFI) >.90 0.9 0.99 
Adjusted GFI (AGFI) >.90 0.86 0.99 
Tucker Lewis Index (TLI) >.90 0.374 0.98 
Comparative Fit Index (CFI) >.90 0.58 0.99 
Root Mean Square Error of Approximation (RMSEA) ≤.09 0.14 0.02 
Hoelter’s Critical N (CN) > 200 91 4,043 
4.5 Structural Equation Modeling with the Measurement Models 
This last step was the formulation of the SEM with the measurement models. The 
statistical process in the SEM allowed for examining how well the data fit the theoretically-
formulated model. As mentioned earlier, two separate models were developed and examined, 
one using LoS and another one for total charge.  
4.5.1 LoS Model 
After revising the models for P, E, and N, a structural equation model with the 
measurement models for LoS was constructed based on the BM: 
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Figure 15. Structural Equation Model with the Measurement Models for LoS and Outcome 
 
As is shown, N had the strongest impact on LoS, P had a very weak one, while E had an 
insignificant relationship with LoS. Regarding O, N was also the strongest component, followed 
by P, and E has no impact on O. There was also an inter-relation between P and N, which 
indicated an indirect effect on LoS and O. CCI, as a control variable, also strongly correlated 
with N.  
Regarding the model’s goodness-of-fit, it seems that the model was not optimally fit 
because the likelihood ratio was 39.6 (Table 11). However, some indicators such as RMSEA and 
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GFI showed that the model was reasonably fit. In addition, additional modifications can be made 
in the model that might improve its fit to the data.  
Table 11.  Goodness-of-Fit Statistics of Generic SEM for LoS 
Fit Indices Criterion Generic Model 
Chi-square (x²) < 5 3128 
Degrees of freedom (df) ≥ 0 79 
Likelihood ratio (x²/df) <4 39.6 
Probability (p or p-close) ≥ .05 0 
Goodness-of-Fit Index (GFI) >.90 0.92 
Adjusted GFI (AGFI) >.90 0.6 
Tucker Lewis Index (TLI) >.90 0.6 
Comparative Fit Index (CFI) >.90 0.7 
Root Mean Square Error of Approximation (RMSEA) ≤.09 0.08 
Hoelter’s Critical N (CN) > 200 156 
 
 
Table 12.  Parameter Estimates for the Generic LoS SEM 
 Generic Model 
Indicator U.R.W S.R.W S.E C.R. P 
LoS <--- N 2.961 0.159 0.281 10.523 *** 
LoS<--- P -0.012 -0.053 0.003 -3.342 *** 
LoS<--- E 0.017 0.005 0.056 0.3 0.764 
Renal_Disease<--- N 1 0.462    
DMII<--- N 0.24 0.13 0.027 8.976 *** 
No_Depression<--- P 0.011 0.379 0.001 17.053 *** 
Dementia<--- P 0.005 0.33 0 16.073 *** 
Hypertension<--- N 0.95 0.396    
HLS<--- P 0.016 0.374 0.001 16.958 *** 
SES<--- E 0.26 0.248 0.058 4.454 *** 
Patient_Loc<--- E 1 0.887    
Urban_hosp<--- E 0.103 0.252 0.023 4.457 *** 
Hyperlipidemia<--- N 0.473 0.182 0.033 14.374 *** 
DM_comp<--- N 1.115 0.511 0.038 29.506 *** 
Severity_of_Adv_outcome <--- P 0.013 0.224 0.001 12.474 *** 
Severity_of_Adv_outcome <--- N 1.175 0.234 0.075 15.718 *** 
Severity_of_Adv_outcome <--- E 0.005 0.005 0.015 0.316 0.752 
Severity_of_Adv_outcome <--- LoS 0.027 0.099 0.004 7.294 *** 
AGE<--- P 1 0.953    
*** . Correlation is significant at the 0.05 level. 
Note: U. R.W. = Unstandardized Regression Weight; S. R. W. = Standardized Regression Weight; S. E. = Standard 
Error; C. R. = Critical Ratio 
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4.5.2 Total Charge Model 
After revising the models for P, E, and N, a structural equation model with the 
measurement models for total charge was constructed based on the BM: 
 
Figure 16. Structural Equation Model with the Measurement Models for Total Charge and 
Outcome 
 
Similar to the LoS model, N in this model had the strongest impact on total charge. 
However, E appeared to have a moderate impact on total charge, while P was the weakest. 
Regarding O, N remained the strongest predictive component, followed by P, and E had no 
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impact on O. The inter-relation between P and N was also present as well as the correlation 
between CCI and N. The model was also reasonably fit, as some of the indices were at the target 
level while others were not. 
Table 13.  Goodness-of-Fit Statistics of Generic and Revised SEM for Total Charge 
Fit Indices Criterion Generic Model 
Chi-square (x²) < 5 3072 
Degrees of freedom (df) ≥ 0 79 
Likelihood ratio (x²/df) <4 38.8 
Probability (p or p-close) ≥ .05 0 
Goodness-of-Fit Index (GFI) >.90 0.93 
Adjusted GFI (AGFI) >.90 0.89 
Tucker Lewis Index (TLI) >.90 0.66 
Comparative Fit Index (CFI) >.90 0.74 
Root Mean Square Error of Approximation (RMSEA) ≤.09 0.08 
Hoelter’s Critical N (CN) > 200 159 
 
Table 14.  Parameter Estimates for the Generic Total Charge SEM 
Indicator U.R.W S.R.W S.E C.R. P 
TOTCHG<--- N 23615 0.168 2138 11.04 *** 
TOTCHG<--- P -88.353 -0.053 26.129 -3.38 *** 
TOTCHG<--- E 4140.641 0.148 779.62 5.31 *** 
Renal_Disease<--- N 1 0.468    
DMII<--- N 0.244 0.135 0.027 9.16 *** 
No_Depression<--- P 0.011 0.378 0.001 17.04 *** 
Dementia<--- P 0.005 0.33 0 16.07 *** 
Hypertension<--- N 0.95 0.402    
HLS<--- P 0.016 0.373 0.001 16.95 *** 
SES<--- E 0.282 0.258 0.047 6.02 *** 
Patient_Loc<--- E 1 0.847    
Urban_hosp<--- E 0.113 0.265 0.019 6.03 *** 
Hyperlipidemia<--- N 0.472 0.184 0.033 14.40 *** 
DM_comp<--- N 1.112 0.517 0.038 29.56 *** 
Severity_of_Adv_outcome <--- P 0.013 0.228 0.001 12.74 *** 
Severity_of_Adv_outcome <--- N 1.103 0.261 0.074 15.00 *** 
Severity_of_Adv_outcome <--- E -0.018 -0.018 0.016 -1.10 0.27 
Severity_of_Adv_outcome <--- TOTCHG 0 0.162 0 11.85 *** 
AGE<--- P 1 0.955       
*** . Correlation is significant at the 0.05 level. 
Note: U. R.W. = Unstandardized Regression Weight; S. R. W. = Standardized Regression Weight; S. E. = Standard 
Error; C. R. = Critical Ratio 
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4.6 Decision Tree Regression (DTREG) Results   
As mentioned earlier, DTREG modeling was conducted on each of the three target 
variables: LoS, total charge, and O to further explore the probability of the different predictor 
(independent) variables on the target (dependent) variable. Initially, only those predictor 
variables under (P, E, and N) that were found significant in path analysis were analyzed 
separately against the target variable. Afterward, an overall decision tree analysis was conducted, 
which included high-impact variables on the target variable. Results of the analysis, as well as 
the decision tree models, are shown following the analysis of each of the target variable. 
4.6.1 DTREG for LoS 
As described above, a separate DTREG analysis was conducted for each of the groups of 
predictor variables influencing LoS. The results of the analysis for the first group (P), including: 
Age, dementia, no_depression, and HLS, showed that age (relative importance =100) was by far 
the most important variable that influenced LoS followed by HLS, no_depression, and dementia 
(relative importance = 18.6, 12.4, 9.5 respectively) (Appendix F, Figure 20). For the (E) group, 
SES was of highest importance followed by patient_loc and then urban_hosp (relative 
importance = 100, 72.1, 63.3 respectively) (Appendix F, Figure 21). Regarding the (N) group, 
the top two predictor variables were DM_comp and renal_disease (relative importance = 100, 
62.5 respectively), followed by hyperlipidemia, DMII, and hypertension (relative importance = 
49.4, 47.15, 45.29 respectively) (Appendix F, Figure 22). 
The results of the path analysis showed a very weak impact of P and E on LoS while N 
had the largest impact (Table 12). Therefore, the overall DTREG analysis for LoS included the 
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following predictor variables: age, SES, DM_comp, renal_disease hyperlipidemia, DMII, and 
hypertension. The results of the analysis revealed that among all factors, age had the highest 
relative impact on LoS, followed by SES, DM_comp, renal_disease, and hypertension 
(Appendix F, Figure 23). The proportion of variance explained by the model (R^2) was 7.3%, 
and RMSE was 3.4. A DTREG tree of the predictors for LoS was generated as well as a 
summary table for the results as shown below: 
 
Figure 17. DTREG Tree of the Predictors for LoS 
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Table 15.  Summary of DTREG Analysis of the Predictors for LoS – ranked from highest to 
lowest 
LoS Score (days) Characteristics 
9.80 Age <22.5, with DM complications, SES 1,2 
6.80 Age >82.5, with DM complications, no renal disease, SES 3,4 
4.90 Age <67.5, with DM complications and Renal disease, SES 3,4 
4.24 Age >22.5, with DM complications, SES 1,2 
3.64 Age >57.5 with no DM complication 
3.24 Age <57.5 with no DM complication 
3.16 Age >67.5, with DM complications and Renal disease, SES 3,4 
3.12 Age <82.5, with DM complications, no renal disease, SES 3,4 
 
The results indicated that those young DM patients who were younger than 22.5 years, 
who have one or more DM complications and who have a lower SES, have the longest LoS. 
Second to them were those elderly DM patients who were older than 82.5 years and at a higher 
SES, with DM complications and no renal disease. On the other hand, shorter LoS was shown 
among those younger than 82.5 years with DM complications. 
4.6.2 DTREG for Total Charge 
Similar steps were conducted for the DTREG analysis with total charge. Again, the 
results of the analysis for the (P) group showed that age (relative importance =100) is by far the 
most important variable that influenced total charge followed by HLS, no_depression, and 
dementia (relative importance = 15.2, 11.2, 7.1 respectively) (Appendix G, Figure 24). For the 
(E) group, patient_loc was the highest importance followed by SES and then urban_hosp 
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(relative importance = 100, 23.7, 13.4 respectively) (Appendix G, Figure 25). Regarding the (N) 
group, the top two predictor variables were renal_disease and DM_comp (relative importance = 
100, 49.3 respectively), followed by DMII, hyperlipidemia, and hypertension (relative 
importance = 27.5, 19.9, 18.6, respectively) (Appendix G, Figure 26). 
Since the path analysis showed that P has a very weak impact on total charge (Table 14), 
the overall DTREG analysis included the following predictor variables: age, patient_loc, SES, 
urban_hosp, renal_disease, DM_comp, and DMII. The results of the analysis indicated that age 
had the highest relative impact on total charge, followed by patient_loc, SES, renal_disease, 
DM_comp, and DMII (Appendix G, Figure 27). The proportion of variance explained by the 
model (R^2) was 11.97%, and RMSE was 25,687. A DTREG tree of the predictors for LoS was 
generated as well as a summary table for the results as shown in Figure 18: 
 
Figure 18. DTREG Tree of the Predictors for Total Charge 
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Table 16.  Summary of DTREG Analysis of the Predictors for Total Charge – ranked from 
highest to lowest 
Total Charge Score Characteristics 
$33,548 Age <81.5 with renal disease, pt. loc 4,5 
$30,329 Age 70-80, pt loc 1,2,3 
$28,426 Pt loc 5 and no Renal disease 
$24,933 Age >81.5 with renal disease, pt. loc 4,5 
$24,074 Pt loc 4 and no Renal disease 
$22,734 Age <70, with DM comp, Pt loc 1,2,3 
$17,829 Age >80, pt loc 1,2,3 
$17,643 Age <70, no DM comp, pt loc 1,2,3 
 
As shown in Table 16, highest charges were associated with those younger than 81.5 
years who are located in larger metropolitan areas and who had renal disease, followed by those 
who were between 70-80 years old and who lived in smaller towns. In contrast, those who were 
younger than 70, had no DM complication and lived in smaller towns had the lowest charges, 
followed by those elderly DM patients who were older than 80 and lived in smaller towns.  
4.6.3 DTREG for Outcome 
The last DTREG analysis was for O. The results of the analysis for the P group showed 
that age (relative importance =100) was the most important variable that influenced O followed 
by HLS, no_depression, and dementia (relative importance = 15.8, 11.2, 6.04 respectively) 
(Appendix H, Figure 28). For the E group, patient_loc had the highest importance followed by 
SES and then urban_hosp (relative importance = 100, 30.5, 17.6 respectively) (Appendix H, 
Figure 29). Regarding the N group, the top two predictor variables were renal_disease and 
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DM_comp (relative importance = 100, 49.3 respectively), followed by DMII, hyperlipidemia, 
and hypertension (relative importance = 27.5, 19.9, 18.6 respectively) (Appendix H, Figure 30). 
Both path analyses showed that E had a minimal impact on O (Table 12 and 14). Thus, 
the overall DTREG analysis for O included the following predictor variables: age, HLS, 
patient_loc, renal_disease, and DM_comp. The results of the analysis indicated that age had the 
highest relative impact on O, followed by renal_disease, patient_loc, HLS, and DM_comp 
(Appendix H, Figure 31). The proportion of variance explained by the model (R^2) was 18.6%, 
and RMSE was 0.8. A DTREG tree of the predictors for LoS was generated as well as a 
summary table for the results as shown in Figure 19: 
 
Figure 19. DTREG Tree of the Predictors for Outcome 
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Table 17.  Summary of DTREG Analysis of the Predictors of Outcome – ranked from worst to 
best 
Outcome Score Characteristics 
1.7 Age > 87.5 with renal disease 
1.36 Age 61.5-87.5 with renal disease 
1.34 Age > 75.5 with no renal disease 
1.08 Age 51.5-61.5 with renal disease 
1.007 Age 61.5-75.5 with no renal disease 
0.97 Age <51.5 with renal disease 
0.7 Age 52.5-61.5 with no renal disease 
0.47 Age <52.5 with no renal disease 
 
The results indicated that the worst outcome was among diabetics who were older than 
61.5 years with a renal disease. Better outcomes were found among those who were younger 
than 61.5 with no renal disease. 
4.7 Hypothesis Testing 
This last section is concerned with reviewing the five hypotheses for this study and 
evaluating whether the results of the study support each one of them.   
4.7.1 Hypothesis One  
The first two hypotheses for this study were about the magnitude of different components 
on utilization. The first one was for LoS: 
Ha1: The magnitude of different components varies with regard to determining the LoS 
among patients who develop HG. 
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The SEM analysis clearly revealed that all the three factors: P, E, and N had different 
impacts on LoS (Table 12). N was found to have the strongest impact on LoS, while P and E had 
a very weak direct impact on LoS. Therefore, hypothesis 1 was supported. 
4.7.2 Hypothesis Two  
The second hypothesis for the study was about the other utilization measure, total charge:  
Ha2: The magnitude of different components varies with regard to determining the total 
cost among patients who develop HG. 
The results of the analysis indicated that N had the strongest impact on total charge, 
followed by E. On the other hand, P seemed to have a very week direct impact on total charge 
(Table 14). Thus, the study results also supported hypothesis 2. 
4.7.3 Hypothesis Three  
The third hypothesis was related to the magnitude of different components on outcome: 
Ha3: The magnitude of different components varies with regard to determining the 
outcome among patients who develop HG. 
The analysis showed that N and P had a stronger direct impact on O when compared to E 
(Table 12 and 14). In addition, both measures for U: LoS and total charge showed a moderate 
impact on the O. Therefore, these findings supported the third hypothesis. 
4.7.4 Hypothesis Four  
The fourth hypothesis is about whether N was the most important predictor for 
utilization: 
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Ha4: The need-for-care component is the most important component of the predictors of 
use, while the effects of other predictors are being simultaneously considered. 
When considering LoS, N showed the strongest significant direct effect on LoS, while P 
had a very weak but significant effect on LoS, and E had a non-significant effect. Regarding total 
charge, all factors showed a statistically significant impact. However, N still had the strongest 
effect (Table 12 and 14). Thus, that hypothesis was supported. 
4.7.5 Hypothesis Five  
The last hypothesis was related to the interaction effects among predictor variables on utilization 
and outcome: 
Ha5: There are statistically significant interaction effects (e.g., P*N, N*E, and E*N) of 
predictor variables on utilization and outcomes. 
When examining the models, we noted that there were no inter-relations between E and 
N. However, there was a strong inter-relation between P and N in the LoS model as well as the 
total charge model (SRW= 0.25 for both models). These findings indicated indirect effects on 
LoS and O. Using SEM, interaction effects can be accurately determined. However, a closer look 
at the DTREG analysis results showed that certain factors had high impact on target variables. 
For example, age, SES, and renal disease each had a high impact. However, the results indicated 
that their effect varied in severity based on the presence or absence of other factors. Hence, an 
interaction effect is present among these factors and therefore the fifth hypothesis was supported. 
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Table 18.  Summary of Hypothesis Testing Results 
Hypotheses Test Result 
Ha1: the magnitude of different components varies with regard to determining the 
LoS among patients who develop HG. 
 
Supported (Positive) 
Ha2: the magnitude of different components varies with regard to determining the 
total cost among patients who develop HG. 
 
Supported (Positive) 
Ha3: the magnitude of different components varies with regard to determining the 
outcome among patients who develop HG. 
 
Supported (Positive) 
Ha4: The need-for-care component is the most important component of the 
predictors of use, while the effects of other predictors are being simultaneously 
considered. 
 
Supported (Positive) 
Ha5: There are statistically significant interaction effects (e.g., P*N, N*E, and 
E*N) of predictor variables on utilization and outcomes. 
 
Supported (Positive) 
 
4.8 Summary of the Chapter  
This chapter presented all the results of the data analysis. Starting with descriptive 
analysis, few variables were excluded from the analysis as they breached the normality 
assumptions. Afterward, correlation analysis showed that none of the remaining variables was 
highly correlated with the other. Then, all measurement models were tested and modified. 
Subsequently, the SEM for LoS and total charge was constructed, and the results were revealed. 
Afterward, DTREG analysis results were discussed for each of the target variables followed with 
a summary of high-impact variables for each target variable. Last, all the five hypotheses were 
examined based on the results of the analysis. Through the various analyses of the data, all five 
hypotheses were supported. More discussion about these results will be in the following chapter. 
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CHAPTER 5 : DISCUSSION, IMPLICATIONS, LIMITATIONS AND 
CONCLUSIONS 
5.1 Summary 
This study had five research questions and five accompanying hypotheses. The study 
findings provided strong support for all of them. The results indicated that different elements in 
the behavior model vary in terms of their impact on the level of utilization and outcome among 
HG patients. The results of the study also revealed that the need-for-care component was the 
most important predictor for length of stay, total charge, and outcome. Moreover, important 
inter-relations were found between some components such as the predisposing and need-for-care 
components, which indicated that these components had indirect impacts on utilization and 
outcome along with their direct ones.  
In this section, the two different elements for utilization: length of stay and total charge will 
be discussed separately, followed by outcome. Afterward, the various implications of the study 
including policy, practical, and theoretical implications were discussed. Then, major limitations of 
the study were presented, followed by recommendations for future research and conclusion. 
5.2 Discussion of the impact of different components on length of stay 
Results of the SEM for length of stay did go along with the theoretical background for 
this study; the results showed that the three different components (predisposing, enabling, and 
need-for-care) had different impacts on utilization. Moreover, the results indicated that the need-
for-care had the strongest effect on the duration of stay with a weight of 0.16 (Table 12). This 
mimics the classical findings of the original developer of the BM, Ronald Andersen (Aday & 
Andersen, 1974; Andersen & Newman, 1973). The predisposing component had a smaller effect, 
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but statistically significant impact on patients’ length of stay. This means that patients with some 
risk factors under the predisposing component or the enabling component will likely be expected 
to stay longer in the hospital. For example, older patients with diabetes complications who are 
located in larger metropolitan areas are expected to spend more time in the hospital. Last, the 
enabling component shows no effect on the duration of stay among diabetic patients with 
hypoglycemia. This means that the socio-economic status and geographical location do not play 
a significant role in determining the duration of stay in hospitals among those patients. Thus, 
when trying to tackle the issue of length of stay among HG patients, this study suggests a focus 
on issues related to factors under the predisposing and need-for-care components rather than the 
enabling one.  
However, this study showed that the main influence on patients’ length of stay is when 
there are factors related to illness, which was clearly demonstrated by the inter-relation between 
the predisposing component and need-for-care. In turn, this finding goes along with the BM, 
where the predisposing component had a weak direct impact on utilization but a stronger indirect 
impact through need-for-care. Thus, patients who have some factors under the predisposing 
component do not necessarily have longer stays in hospital unless they have other factors under 
the need for care component. This means that patients who have renal disease and diabetes 
complications are more likely to stay longer in hospitals if they are older and have dementia. In 
contrast, older patients with dementia are not likely to stay longer in hospitals if they do not 
show any diabetes complication, renal diseases, or other factors under the need-for-care 
component. 
These findings also support the findings from other studies in which certain factors such 
as dementia, tobacco use, alcohol use, or drug use played an important role in patients’ behavior, 
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including adherence to medication, regular follow-ups for screening and prevention, and self-
care measures. Consequently, those patients demonstrated more comorbidities and illnesses, 
which lead to longer stays in the hospital. 
Another finding is related to comorbidities, demonstrated as the control variable CCI. 
Since these comorbidities have a great impact on utilization and outcome, the CCI variable was 
applied as a controlled variable in an attempt to hold it constant during the statistical analysis in 
order to test the relative relationship among the main component in the model. The strong 
correlation between comorbidities and the need-for-care component shown in the results was 
expected because of the great number of previous studies that reported the impact of different 
comorbidities on the severity of illness among HG patients. This relationship provides great 
knowledge to healthcare providers when considering the issue of length of stay among HG 
patients. This is because comorbidities seem to have a major impact on the severity of illness as 
well as the health consequences among HG patients. Therefore, investing more effort and time in 
treating those comorbidities might help to reduce the severity of HG episodes as well as the 
duration of stay in hospitals. 
Along with the SEM results, the DTREG results of this study showed that age was the 
most important predictor variable among all the other indicators under the predisposing 
component. Elderly diabetic patients have been consistently shown to have higher risks for 
developing HG as well as developing complications, staying longer in the hospital, and acquiring 
higher total costs (Geller et al., 2014; Kong et al., 2014; Majumdar et al., 2013; Pathak et al., 
2015). on the other hand, patient’s socio-economic status was found to have the strongest impact 
on length of stay among all different factors under the enabling component. Again, based on the 
theoretical background of this study, the presence of factors under the need-for-care component 
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is crucial to impact utilization. The results of this study showed that the presence of DM 
complications and renal disease, which are factors under the need-for-care component, played a 
vital role in impacting length of stay (Table 15). These findings in the DTREG analysis explain 
the indirect impact of predisposing and enabling components on length of stay that was revealed 
in the SEM.    
5.3 Discussion of the impact of different components on total charge 
When exploring the results of the SEM for the second element of utilization, total charge, 
this study found once more that the three different components had different impacts on 
utilization, with the need-for-care being the strongest with a S.R.W of 0.17 (Table 14). Thus, 
patients who have some factors under the need-for-care component are more likely to incur 
higher charges, regardless the presence or absence of any other factors under the predisposing or 
enabling component. However, the results also show inter-relations between the predisposing 
and the need-for-care components. This means that some factors such as patients’ age and 
dementia can have an impact on the total charge if there are other factors under the need-for-care 
component such as renal disease and hypertension present in the patient. Likewise, the DTREG 
results showed that the presence of renal disease and DM complication, as factors under the 
need-for-care component, were the key factors in defining the total charges associated with the 
admission. Yet, higher chargers were found to be among older patients, a factor under the 
predisposing component, who have renal diseases and DM complications. 
Regarding comorbidities, the findings in the total charge model are similar to those in the 
length of stay model. The results show a great relation between comorbidities and the need-for-
care component. This means that patients with a higher comorbidity index are more likely to 
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incur higher charges for their admission. Thus, when considering reducing the charges among 
HG patients, it is important to invest more time and effort in treating other comorbidities 
associated with those patients.    
Another finding is related to the enabling component in the total charges model. While 
there was no impact of the enabling component on length of stay, there is a relatively strong and 
statistically significant impact of the enabling component on total chargers. These findings 
indicated that patients with higher socio-economic status, living in larger metropolitan areas, and 
visiting urban hospitals incurred higher charges than their counterparts in rural areas. Parallel 
findings were found in the results of DTREG analysis as patients living in larger metropolitan 
areas with a higher SES incurred higher charges than the others. These findings were contrary to 
what was reported in the literature, which was that patients in smaller towns usually had higher 
ED visits as well more severe HG episodes (Andrus et al., 2004; Babitsch et al., 2012; Chen et 
al., 2015; Conwell & Boult, 2008; Ginde et al., 2008; Rosenblatt et al., 2001; Unger et al., 2011; 
Weiner et al., 1995). One explanation for the discrepancy might be that smaller hospitals in rural 
areas provide only essential services with no follow-up services (Broyles et al., 1999; Thode et 
al., 2005), therefore resulting in fewer charges. Another possibility for the difference is that 
because patients with lower SES who live in smaller towns are sicker, some of them die in the 
hospital and hence incur fewer charges than their counterparts who survive. 
5.4 Discussion of the impact of different components on outcome 
Results regarding outcome are very similar between the models of length of stay and total 
charges. The ranking is as follows: need-for-care component had the highest impact on outcome, 
followed by the predisposing component, then utilization, while the enabling component had the 
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weakest impact on outcome. This means that patients with more severe illness status were more 
likely to have worse outcomes, regardless the presence of any other factors under all other 
components. However, the impact of the other two components, predisposing and enabling, can 
be demonstrated indirectly through the need-for-care component. Also, comorbidities are shown 
to indirectly impact outcomes. Thus, the outcome could be expected to get worse among patients 
who have some factors under the need-for-care components as well as other factors under the 
two other component or other comorbidities. For example, older diabetic patients who develop 
HG usually have more comorbidities and thus were expected to have very poor outcomes when 
compared to younger patients. The DTREG results also revealed the same findings (Table 16), 
where older patients with renal disease demonstrated more adverse outcomes, while younger 
patients with no renal disease had the best outcomes. In conclusion, in order to improve the 
outcomes among HG patients, efforts should focus on factors under the need-for-care component 
such as treating underlying renal disease and DM complications. Also, other high impact factors 
under the other components such as age, dementia, and comorbidities can impact the outcome 
and they need to be considered as well when trying to improve the outcome among HG patients.    
5.5 Implications 
5.5.1 Policy Implications 
Florida is one of the largest states in terms of the percentage of adults with diabetes, and 
the three Central Florida counties of Orange, Osceola, and Seminole are close to Florida’s 
average of over 10% of adults diagnosed with diabetes in 2013 (Floridacharts.com, 2016) and 
more than 26% of adults being obese. In 2014 alone, there were more than 36,000 
hospitalizations in Orange county related to diabetes (Floridacharts.com, 2016). According to a 
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2013 Central Florida community health needs assessment report, diabetes is the most prevalent 
chronic disease in the region, is a leading cause of death, and is therefore considered one of the 
top five health priorities in the region (Floridahospital.com, 2013).  
Results of this study also showed that the geographical location of diabetic patients with 
HG impacts the level of utilization as well as outcome. Recent data about the geographical 
distribution of diabetes in Florida shows that 14% of adults in urban areas have diabetes, 
compared to 15.5% in suburban areas and 18.7% in rural areas (UnitedHealthFoundation, 2016). 
A recent study conducted in eight southeastern states also showed racial disparities in diabetes 
hospitalization of rural Medicare beneficiaries (Wan, Lin, & Ortiz, 2016). Therefore, this study 
suggests that more effort is needed toward residents in rural areas. These measures might include 
conducting community needs assessments to evaluate the availability of healthcare services in 
patients’ neighborhoods as well as examining what other challenges are present among those 
residents that might affect their diabetes-related care. 
Another major finding of this study is the great impact of age on utilization and outcome 
among diabetic patients with HG. In Florida, most of the state’s counties have older populations 
than do counties in the U.S. overall (Reynolds, Gunderson, & Bamford, 2015), and the number 
of Floridians aged 85 and older increased by about 4% from 2000 to 2010 (Reynolds et al., 
2015). Additionally, the rate of ED visits for diabetics who are 75 and older increased 44% from 
2009 to 2014 (Floridahospital.com, 2013). At the county level, it is estimated that by 2025, 
Orange county will have the highest number of people aging 65 and older with over 215,000 and 
accounting for 14% of the county’s population (Appendix J, Table 27). In contrast, Seminole 
county have the highest percentage of elderly people in Central Florida and it is estimated that 
this percentage will reach 18% in 2025 (Appendix J, Table 27). When specifically examining 
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certain races such as Blacks and Hispanics, Osceola county shows the highest percentage of 
elderly people among those races (Appendix J, Table 27). Thus, this study indicates a 
recommendation for decision makers in Central Florida to develop certain strategies targeting 
older diabetic patients in Orange and Seminole counties to improve their health literacy, enhance 
their adherence to medications, and be more encouraged to perform regular prevention and 
screening visits. In addition, certain strategies can be formulated to target elderly Blacks and 
Hispanics living in Osceola county. 
Another issue is that the findings of this study show relationships between old age, 
comorbidities, HG severity, Socio-economic status, and living in rural areas with the level of 
utilization and the severity outcomes. Recent statistics show that Osceola county has the highest 
percentage increase of disabled people younger than 65 years from 2011-2015 in Central Florida 
(Appendix J, Table 27). Moreover, when compared to the other two counties in Central Florida, 
Osceola county has the highest percentage of uninsured people younger than 65 years, the lowest 
median household income, and the highest number of persons in poverty (Appendix J, Table 27). 
Orange county, on the other hand, has the highest increase in the number and percentage of 
veterans from 2011-2015 (Appendix J, Table 27). Therefore, with a transdisciplinary approach, 
policy makers might need to consider those issues to implement better strategies to reduce the 
growing negative economic and social impact of the HG problem among diabetic Floridians. To 
approach such a huge problem, a collaboration among different sectors and stakeholders, 
including health care providers, social workers, policy makers, financial experts, health 
educators, community leaders, and other experts is called for in order to understand the size of 
the problem, discuss the challenges from all perspectives, examine successful strategies 
implemented in other areas, propose some policy options, and then choose the best feasible 
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option. This approach will ensure the implementation of better strategies that are economically 
and practically feasible. In addition, including experts from different disciples will provide a 
larger pool of knowledge, which could reduce potential mistakes and increase success. 
Last, there are some difference between the three counties in Central Florida regarding 
their racial profile. The 2017 estimates show that Osceola county has the highest percentage of 
Hispanic population, Orange county has the highest percentage of African Americans, while 
Seminole county has the highest percentage of White people (Appendix J, Table 27). From 2010-
2014, The percentage of Hispanics increased the highest in Osceola county while the number of 
Hispanics increased the highest in Orange county (Appendix J, Table 27). Although this study 
showed that racial difference did not play a significant role in impacting the utilization and 
outcome among HG patients, it is important for policy makers to consider the racial differences 
between the three counties especially when developing certain educational or behavioral 
modification policies and strategies. 
5.5.2 Theoretical Implications  
The BM offers a framework for examining the impact of different risk factors for HG 
utilization and outcome. Employing SEM to analyze the magnitude of effects of different factors 
provided a conceptual understanding of the relationship between all the components of the BM. 
Moreover, the BM emphasizes the direct and indirect impact of different components on 
utilization and outcome. Thus, the use of advanced statistical methodologies such as SEM was 
crucial to examining these relationships and showing the difference between the direct and 
indirect impacts of each component on utilization and outcome. In addition, each of the 
components was conceptualized and examined separately as a latent construct. This provided in-
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depth knowledge regarding each of the different risk factors under each component and the 
presence of any inter-relations among them.  
The BM theoretical base of the study also played a vital role when applying DTREG 
analysis. Rather than including all factors into one single inquiry, certain factors were grouped 
together based on the component they are related to. This approach provided a 
comprehensiveness to each component in terms of the most important factors in each group that 
influenced the target variable. Consequently, only high impact factors under each component 
were included in the final analysis. This approach provided more accurate and interpretable 
results that are also more practical. 
5.5.3 Practical Implications  
With recent transition toward the value-based payments (VBP), healthcare providers are 
being encouraged to deliver more high-quality services at lower cost (CMS.gov, 2017). This is 
because their reimbursement is now based on quality rather than quantity of visits or the number 
of services provided (Wagner, 2015). In addition, stakeholders impose continuous pressure on 
healthcare organizations to provide sustainable, high quality, and cost-effective services 
(Ramirez, West, & Costell, 2013). Therefore, understanding which groups are at high risk for 
developing complications or using more services for a common disease such as DM is crucial for 
healthcare providers (Henkel & Maryland, 2015). 
This study revealed that certain groups are at higher risk of longer stays in hospitals, 
higher total charges, and worse outcomes. Hospitals can employ a digital predictive model to 
help identify those high-risk patients and proactively provide the best care for them. Also, 
healthcare providers can target this group with educational interventions by employing the 
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Knowledge, Attitude, Preventive Practice, and Outcomes (KAP-O) framework to improve their 
health status, prevent severe adverse outcomes, and reduce their level of healthcare utilization  
(Marathe, Wan, & Marathe, 2016; Wan, 2014). Last, collaborations among different levels of 
providers: clinics, hospitals, long-term, and post-acute care organizations might also facilitate 
monitoring wearable devices among high-risk DM patients to prevent HG episodes (Clarka , 
Elswickb, Gabrielb, Gurupur, & Wisniewski, 2016). 
5.6 Limitations  
Although this study is robust and provided rich knowledge about different HG risk 
factors and their impact on utilization and outcome, there were certain limitations. First, the 
study used secondary data, which is on one hand the largest national database available. On the 
other hand, the nature of secondary data usually limits the number of variables to the ones that 
are already accessible in the database. So, some variables, such as patients’ educational 
attainment, the presence of a primary care physician, duration of DM, history of previous HG, 
medications used, and whether the patient was transferred to ICU or not, would be important 
when examining HG risk factors, but they were not recorded in the database. Also, some 
variables that were already included in the database need further clarification to be useful. For 
instance, the data did not differentiate between those who were admitted with HG from those 
who developed HG after admission. Another issue is that because the database included only 
inpatient data, only short-term in-hospital complications were captured. Thus, long-term 
complications, such as readmissions and mortality after discharge could not be captured. 
Moreover, other HG patients who sought medical assistance through clinics or other avenues 
also were not captured. 
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 Last, there were some assumptions related to the data used in this study. The first 
assumption was that any diagnosis that was not recorded in the patients’ ICD codes was 
considered to be absent. However, because of the nature of the ICD coding and its sole purpose 
for medical billing, there were some occasions in which some problems happened to patients and 
might have been recorded in the doctors’ notes, but they were not recorded under the patients’ 
ICD codes because the hospital would not have been reimbursed for them. These missing pieces 
of information lead to a second assumption about the accuracy of the data: since there was no 
way to check the accuracy of data entry in the database, the study assumed that all data are 
accurate. The last assumption relates to some variables. For example, the study assumed all 
patients had one source of insurance coverage, as the data recorded only one type of insurance 
provider for each patient. However, there are some patients with dual insurance, such as 
Medicaid and Medicare. Unfortunately, information about patients with dual insurance could not 
be attained, so the assumption made for this study was that all patients had only one single 
insurance provider. 
5.7 Recommendations for Future Research 
It is recommended that future studies be designed in a prospective format, which could 
allow for the inclusion of some other key variables. Therefore, it is suggested that variables such 
as the duration of DM (Amiel, Dixon, Mann, & Jameson, 2008; Karges et al., 2015), type of 
glucose-lowering medications (Chan & Colagiuri, 2015; Handelsman, Bode, Endahl, Mersebach, 
& King, 2015; Heller, Frier, Herslov, Gundgaard, & Gough, 2015; Monami et al., 2014; 
Thompson, 2015), type of antibiotics (Dzygalo, Kowalska, & Szypowska, 2015; Kendall & 
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Wooltorton, 2006) and transfer to ICU (Gangji, Gerstein, Goldsmith, & Clase, 2007; Hermanides 
et al., 2010) be included in further studies that would explore their impact on HG U and O. 
In addition, it is recommended that further research be conducted concerning the timing 
and frequency of HG episodes among admitted patients as well as separating those who come to 
ED with HG from others who develop in-hospital HG. Another area that needs further 
exploration is related to the pattern of HG episodes across the month. HG events usually occur 
when there are disturbances in patients’ diet or their intake, and end-of-month exhaustion of food 
budgets among low SES patients contribute to the increase of HG occurrence during that time of 
the month (Seligman, Bolger, Guzman, López, & Bibbins-Domingo, 2014). 
Another area of possible future research would be to explore the long-term HG effects 
such as readmissions (Majumdar et al., 2013), history of HG, and annual frequency of HG 
(Hirsch et al., 2012; Kaur, Markley, Schlauch, & Izuora, 2015), as well as other complications 
that are treated in outpatient settings. Last, HG can occur among diseases other than diabetes. So, 
it might also be important to conduct studies that examine HG among non-diabetic patients and 
their risk factors, utilization, and outcomes to compare them to patients with diabetes.  
5.8 Conclusions 
To the best of our knowledge, the present study is the first study aimed at examining the 
multilevel character of a variety of factors that contribute to HG and their effects on utilization 
and outcome while employing Andersen’s BM. This study’s use of the largest national inpatient 
database combined with the robust analytical methods used provided rich information about the 
matter. On one hand, SEM helped in testing multiple hypotheses developed for the study as well 
as exploring the direct and indirect impact of different factors on utilization and outcome. On the 
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other hand, by conducting DTREG analysis, the study further explored the probability of the 
various predictor variables on length of stay, total charge, and outcome, which provided a better 
picture about HG risk factors and their individual impacts on each target variable.  
Thus, especially in light of the current shift toward VBP, these results provide practical 
applications for healthcare providers as they could be used as predictors of HG among diabetic 
patients. Based on the study findings, healthcare providers can more easily proactively deal with 
the high risk groups who are elderly patients with comorbidities, who have diabetes-related 
complications, and who present with renal disease. Targeting those groups could help reduce the 
frequency and severity of HG episodes. Consequently, better results could be achieved, such as 
shorter hospital stays, less cost, and better health outcomes. 
The study results also have great policy implications for decision makers regarding how 
to approach the growing problem of DM in the area of Central Florida. One major finding is the 
pronounced impact of age on all different target variables in this study: length of stay, total 
charges, and outcome. With the increasing number of older people and diabetes in Central 
Florida, policy makers need to integrate innovative policies with collaboration among different 
stakeholders and experts to enhance patients’ levels of self-care and adherence to recommended 
care. Another finding is related to the geographical locations of the DM patients. In Florida, the 
percentage of diabetes is higher in the rural areas of the state. Thus, in-depth assessments of 
these areas regarding access to care, level of healthcare provided, and barriers to care among DM 
patients residing there is critical. These assessments could help reduce the unpleasant medical, 
social, and economic consequences of HG among those groups. 
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Table 19. Previous studies related to HG risk factors, utilization, and outcomes  
Authors, year Diabetes types Factors examined Utilization Outcomes 
 
Studies on HG risk factors among primary care-related HG 
 
  (Sämann et al., 2013) T1DM, T2DM incidence No utilization No outcomes 
  (Kostev et al., 2014) T2DM insulin-treated No utilization No outcomes 
  (Fiallo-Scharer et al., 2011) T1DM CGM No utilization No outcomes 
  (Bordier et al., 2015) T2DM elderly 70+ No utilization No outcomes 
  (Cox et al., 2007) T1DM, T2DM CGM No utilization No outcomes 
  (Bruderer et al., 2014) T2DM incidence No utilization No outcomes 
  (Giorda et al., 2015) T1DM incidence No utilization No outcomes 
  (Sonoda et al., 2015) T2DM insulin-treated No utilization No outcomes 
  (Weinstock et al., 2015) T1DM insulin-treated among 
elderly 
No utilization No outcomes 
  (Kostev et al., 2015) T2DM insulin-treated, 
compare regimen 
No utilization No outcomes 
  (Edridge et al., 2015) T2DM incidence No utilization No outcomes 
  (Ginde et al., 2008) T1DM, T2DM incidence No utilization No outcomes 
  (UKHSG, 2007) T1DM, T2DM HG agent No utilization No outcomes 
  (Gold et al., 1997) T1DM Insulin-dependent 
DM, fear, awareness 
No utilization No outcomes 
 
Studies on HG utilization among primary care-related HG 
 
  (Mier et al., 2012) T2DM no factors physician 
visits, eye 
exam, ED 
No outcomes 
  (Simeone & Quilliam, 2012) T2DM no factors Ed/OPD visit No outcomes 
  (Gu et al., 2015) T2DM no factors hospitalization No outcomes 
  (Liatis et al., 2015) T1DM, T2DM no factors ED visits No outcomes 
  (Davis et al., 2010) T2DM no factors ED/ 
Ambulance/ 
hospitalization
s 
No outcomes 
  (Williams et al., 2012) T2DM no factors office visits, 
ED, 
hospitalization
s LoS and cost 
No outcomes 
  (Quilliam et al., 2011) T2DM no factors office visits, 
ED, 
No outcomes 
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hospitalization
s 
  (Majumdar et al., 2013) T2DM no factors hospitalization
s 
No outcomes 
  (Fayfman et al., 2016) T1DM, T2DM no factors ED, 
hospitalization
s  
No outcomes 
  (Quilliam et al., 2011) T2DM no factors hospitalization No outcomes 
  (Duran-Nah et al., 2008) T2DM no factors hospitalization No outcomes 
 
Studies on HG outcomes among primary care-related HG 
 
  (Kong et al., 2014) T2DM no factors clinic FU death and 
cancer 
  (Simon et al., 2015) T2DM no factors No utilization QoL, Fear 
  (Sako et al., 2015) T1DM, T2DM no factors hospitalization mortality 
 
Studies on hospital-related HG 
 
  (Farrokhi et al., 2012) T2DM non-critically ill 
diabetics 
No utilization No outcomes 
  (Schloot et al., 2016) T2DM sulfonylurea No utilization No outcomes 
  (Lin et al., 2010) T2DM Recurrent HG No utilization No outcomes 
  (Pathak et al., 2015) T2DM ED and inpatient No utilization No outcomes 
  (Elliott et al., 2012) T2DM Treatment and HG No utilization No outcomes 
  (D'Netto et al., 2015) T1DM, T2DM Recurrent HG No utilization No outcomes 
  (Abdelhafiz et al., 2012) NA non-diabetics No utilization No outcomes 
  (Gómez et al., 2015) T2DM descriptive statistics No utilization No outcomes 
  (Dendy et al., 2014) T1DM, T2DM hospitalized with DM 
developed SH 
No utilization No outcomes 
  (Deusenberry et al., 2012) T2DM hospitalized with DM 
developed HG 
No utilization No outcomes 
  (Vriesendorp et al., 2008) T2DM ICU No utilization septic shock, 
ventilator, etc. 
  (Olveira et al., 2015) T2DM TPN patients insulin No utilization Mortality 
  (Brodovicz et al., 2013) T2DM Chronic LoS Mortality 
  (Chevalier et al., 2016) T1DM, T2DM no factors cost, LoS Mortality, 
fractures, falls 
  (Curkendall et al., 2009) T1DM, T2DM no factors LoS Mortality 
  (Zapatero et al., 2014) T2DM age sex only LoS Mortality, 
readmission 
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  (Turchin et al., 2009) T2DM descriptive stat LoS Mortality 
 
Studies on drugs and HG  
 
  (Czech et al., 2015) T1DM, T2DM systematic review 
and meta-analysis 
No utilization No outcomes 
  (Schopman et al., 2014) T2DM sulfonylurea, 
systematic review 
and meta-analysis 
No utilization No outcomes 
  (Murad et al., 2009) T2DM systematic review 
and meta-analysis 
No utilization death, HG, 
infection, 
stroke, MI 
  (Home et al., 2010) T2DM insulin-treated, 
Systemic meta 
ED/ 
hospitalization 
No outcomes 
  (Geller et al., 2014) T2DM Insulin-treated DM ED/ 
hospitalization 
No outcomes 
  (Solomon et al., 2013) T2DM insulin type ED/ 
hospitalization 
No outcomes 
  (Cariou et al., 2015) T1DM, T2DM insulin-treated hospitalization trauma 
 
  
112 
APPENDIX B: PREVIOUS STUDIES THAT EMPLOYED THE BM 
  
113 
Table 20. Previous studies that employed the BM  
Authors, year Issue examined Utilization 
 
General non-HG studies that employed BM 
 
  (Rhoades et al., 2014) Homeless mental health utilization OPD, hospitalization, counseling 
  (Wan & Yates, 1975) Dental services utilization   
  (Springer, 2015) factors mental health utilization OPD, hospitalization 
  (Manski et al., 2013) older American HC utilization OPD, Hospitalization, Surgery, Home 
health 
  (Matthews, 1990) Predictors to access to home 
service 
  
  (Ko, 2015) Mental help seeking behavior    
  (Akobirshoev, 2015) Parental insurance and health on 
child utilization 
  
  (Clement, 2015) Psychological factors in older rural 
health care use 
OPD, ED 
  (Scheetz, 2010) Utilization in old OPD, Hospitalization, Surgery, Home 
health 
  (Wilkinson-Lee, 2008) Ethnicity and Utilization Testing and screening 
  (Mallya, 2006) Asthma insurance and utilization medication use, OPD, hospitalization, ED 
  (Blaskowitz, 2014) Adults with developmental 
disability utilization 
Ed, hospitalization 
  (Bazargan et al., 1998) AA Utilization Ed, hospitalization 
  (Roberge, 2008) utilization Children with public 
insurance  
ED  
  (Wolinsky et al., 1995) older adults utilization OPD, hospitalization 
  (Kilany, 2014) Mental illness utilization OPD 
  (Snih et al., 2006) HC utilization older Mexican 
American 
LoS, OPD 
 
Diabetes-related studies that employed BM 
 
  (Patel et al., 2015) T2DM Medical adherence 
  (Yeboah-Korang et al., 
2011) 
T2DM Racial differences Healthcare use 
  (Ou et al., 2012) T2DM Prediction of HC utilization and outcomes. 
OPD, hospitalization, ED 
  (Yamashita et al., 2012) T2DM Prediction of adherence and self-care 
  (Gucciardi et al., 2009) T2DM use of educational programs 
  (Hu et al., 2015) T1DM and T2DM Medical expenditure in DM 
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  (Baumeister et al., 2015) T1DM and T2DM Eye care exam use 
  (Chandler & Monnat, 
2015) 
T1DM and T2DM Racial differences 
  (Gamble & Chang, 
2014) 
T2DM OPD 
  (DeLawnia et al., 2014) T1DM and T2DM Eye care exam use 
  (Shenolikar, 2006) T1DM and T2DM Racial differences related to medication 
adherence and utilization: hospitalization 
ED, cost 
  (Jayawant, 2008) T2DM Medicaid patients hospitalization ED, cost 
 
BM studies using SEM 
 
  (Chern et al., 2002) expenditure cost 
  (Stein et al., 2012) Vulnerable population OPD, hospitalization, ED 
  (Wan & Soifer, 1974) physician utilization physician utilization 
  (Stein et al., 2007) Vulnerable population HC use in 
homeless women 
OPD, hospitalization 
  (Tan, 2009) Utilization of older Asians in the 
USA 
LoS, hospitalization, OPD 
  (LaHousse, 2009) Factors utilization of 
mammography screening 
screening 
  (Stein, Andersen, 
Koegel, & Gelberg, 
2000) 
Utilization with cerebral palsy 
adults 
OPD, hospitalization 
  (Brook et al., 2014) Utilization of mental services by 
minority adults 
OPD 
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Table 21. Frequency Table for the Categorized Variables 
Variable Name Value Frequency Percent Valid Percent Cumulative Percent 
Sex 0 2,505 51.9 51.9 51.9 
 
1 2,317 48.1 48.1 100.0 
  Total 4,822 100.0 100.0   
AA_Hisp 0 3,282 68.1 68.1 68.1 
 
1 1,540 31.9 31.9 100.0 
  Total 4,822 100.0 100.0   
Dementia 0 4,445 92.2 92.2 92.2 
 
1 377 7.8 7.8 100.0 
  Total 4,822 100.0 100.0   
No_Depression 0 1,894 39.3 39.3 39.3 
 
1 2,928 60.7 60.7 100.0 
  Total 4,822 100.0 100.0   
HLS 0 525 10.9 10.9 10.9 
 
1 1,002 20.8 20.8 31.7 
 
2 3,295 68.3 68.3 100.0 
  Total 4,822 100.0 100.0   
Urban_hosp 0 1,096 22.7 22.7 22.7 
 
1 3,726 77.3 77.3 100.0 
  Total 4,822 100.0 100.0   
Patient_Loc 1 187 3.9 3.9 3.9 
 
2 441 9.1 9.1 13.0 
 
3 433 9.0 9.0 22.0 
 
4 1,033 21.4 21.4 43.4 
 
5 2,728 56.6 56.6 100.0 
  Total 4,822 100.0 100.0   
SES 1.00 1,580 32.8 32.8 32.8 
 
2.00 1,418 29.4 29.4 62.2 
 
3.00 1,034 21.4 21.4 83.6 
 
4.00 790 16.4 16.4 100.0 
  Total 4,822 100.0 100.0   
Medicaid 0 3,898 80.8 80.8 80.8 
 
1 924 19.2 19.2 100.0 
  Total 4,822 100.0 100.0   
CCI 0 1,209 25.1 25.1 25.1 
 
1 894 18.5 18.5 43.6 
 
2 835 17.3 17.3 60.9 
 
3 609 12.6 12.6 73.6 
 
4 445 9.2 9.2 82.8 
 
5 297 6.2 6.2 88.9 
 
6 179 3.7 3.7 92.7 
 
7 126 2.6 2.6 95.3 
 
8 113 2.3 2.3 97.6 
 
9 45 .9 .9 98.5 
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10 30 .6 .6 99.2 
 
11 15 .3 .3 99.5 
 
12 11 .2 .2 99.7 
 
13 5 .1 .1 99.8 
 
14 4 .1 .1 99.9 
 
15 4 .1 .1 100.0 
 
16 1 .0 .0 100.0 
  Total 4,822 100.0 100.0   
DM_comp 0 3,709 76.9 76.9 76.9 
 
1 1,113 23.1 23.1 100.0 
  Total 4,822 100.0 100.0   
UncontDM 0 3,684 76.4 76.4 76.4 
 
1 1,138 23.6 23.6 100.0 
  Total 4,822 100.0 100.0   
DMII 0 702 14.6 14.6 14.6 
 
1 4,120 85.4 85.4 100.0 
  Total 4,822 100.0 100.0   
Under_wt 0 4,346 90.1 90.1 90.1 
 1 476 9.9 9.9 100.0 
  Total 4,822 100.0 100.0   
Hyperlipidemia 0 2,875 59.6 59.6 59.6 
 
1 1,947 40.4 40.4 100.0 
  Total 4,822 100.0 100.0   
Renal_Disease 0 3,442 71.4 71.4 71.4 
 
1 1,380 28.6 28.6 100.0 
  Total 4,822 100.0 100.0   
Liver_Dis 0 4,547 94.3 94.3 94.3 
 
1 275 5.7 5.7 100.0 
  Total 4,822 100.0 100.0   
Hypertension 0 1,143 23.7 23.7 23.7 
 
1 3,679 76.3 76.3 100.0 
  Total 4,822 100.0 100.0   
Cancer 0 4,443 92.1 92.1 92.1 
 
1 379 7.9 7.9 100.0 
  Total 4,822 100.0 100.0   
Outcome 0 2,524 52.3 52.3 52.3 
 
1 332 6.9 6.9 59.2 
 
2 1,894 39.3 39.3 98.5 
 
3 72 1.5 1.5 100.0 
  Total 4,822 100.0 100.0   
Year 2012 1,605 33.3 33.3 33.3 
 
2013 1,609 33.4 33.4 66.7 
 
2014 1,608 33.3 33.3 100.0 
 
Total 4,822 100.0 100.0  
  
118 
APPENDIX D: HISTOGRAMS FOR THE VARIABLES 
  
119 
  
  
  
120 
 
 
 
 
 
 
121 
 
 
 
 
 
 
 
122 
  
  
  
123 
  
  
  
 
 
 
  
124 
APPENDIX E: SPEARMAN'S RHO CORRELATIONS 
  
125 
Table 22. Spearman's rho Correlations for (P) 
    Age Sex AA_ Hisp 
Deme
ntia 
No_ 
Depre
ssion 
HLS CCI LoS 
TOT 
CHG 
Out 
come 
Ye
ar 
Age Correlation 
Coefficient 
1.00                     
p-value 
           
Sex Correlation 
Coefficient 
0.00 1.00 
         
p-value 0.87 
          
AA
_  
His
p 
Correlation 
Coefficient 
0.01 .069*
* 
1.00 
        
p-value 0.70 0.00 
         
De
men
tia 
Correlation 
Coefficient 
.324** .029* -0.01 1.00 
       
p-value 0.00 0.04 0.39 
        
No_ 
Dep
ress
ion 
Correlation 
Coefficient 
.370** -
.069*
* 
.165** .112** 1.00 
      
p-value 0.00 0.00 0.00 0.00 
       
HL
S 
Correlation 
Coefficient 
.385** .101*
* 
.070** .135** .263** 1.00 
     
p-value 0.00 0.00 0.00 0.00 0.00             
CCI Correlation 
Coefficient 
.341** -
.034* 
.082** .164** .228** .190** 1.00 
    
p-value 0.00 0.02 0.00 0.00 0.00 0.00 
     
LoS Correlation 
Coefficient 
.083** 0.01 -0.03 .061** -.061** 0.01 .202** 1.00 
   
p-value 0.00 0.54 0.07 0.00 0.00 0.53 0.00 
    
TO
T 
CH
G 
Correlation 
Coefficient 
.069** -
.031* 
0.03 .035* 0.00 0.00 .205** .654** 1.00 
  
p-value 0.00 0.03 0.06 0.02 0.79 0.91 0.00 0.00 
   
Out
com
e 
Correlation 
Coefficient 
.338** -
.051*
* 
0.02 .124** .194** .133** .343** .165** .205** 1.00 
 
p-value 0.00 0.00 0.17 0.00 0.00 0.00 0.00 0.00 0.00 
  
YE
AR 
Correlation 
Coefficient 
0.00 0.01 0.00 0.00 -0.02 0.00 0.01 -0.01 .034* 0.00 1.0
0 
p-value 0.95 0.58 0.82 0.78 0.22 0.84 0.61 0.60 0.02 0.99   
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 23. Spearman's rho Correlations for (E) 
    
Urban_ 
hosp 
Patient 
_Loc 
SES Medicaid CCI LoS 
TOT 
CHG 
Outcome 
YE
AR 
 
Urban_ 
hosp 
Correlation 
Coefficient 
1.00 
        
 
p-value 
         
 
Patient_ 
Loc 
Correlation 
Coefficient 
.186** 1.00 
       
 
p-value 0.00 
        
 
SES Correlation 
Coefficient 
.057** .211** 1.00 
      
 
p-value 0.00 0.00 
       
 
Medi 
caid 
Correlation 
Coefficient 
.050** .042** -
.127** 
1.00 
     
 
p-value 0.00 0.00 0.00             
 
CCI Correlation 
Coefficient 
.035* .046** 0.01 -.121** 1.00 
    
 
p-value 0.02 0.00 0.51 0.00 
     
 
LoS Correlation 
Coefficient 
.032* 0.00 -
.050** 
-.031* .202** 1.00 
   
 
p-value 0.02 0.89 0.00 0.03 0.00 
    
 
TOT 
CHG 
Correlation 
Coefficient 
.092** .175** .033* -0.02 .205** .654** 1.00 
  
 
p-value 0.00 0.00 0.02 0.28 0.00 0.00 
   
 
Out 
come 
Correlation 
Coefficient 
0.02 .039** .029* -.108** .343** .165** .205** 1.00 
 
 
p-value 0.29 0.01 0.04 0.00 0.00 0.00 0.00 
  
 
YEAR Correlation 
Coefficient 
.197** .031* -0.02 .031* 0.01 -0.01 .034* 0.00 1.00 
 
p-value 0.00 0.03 0.22 0.03 0.61 0.60 0.02 0.99   
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 24. Spearman's rho Correlations for (N) 
    CCI 
DM_ 
comp 
Uncon
t DM 
DMII 
Hyper-
lipi 
demia 
Renal
_ 
Diseas
e 
Hyper-
tension 
LoS 
TOT 
CHG 
Out-
come 
Y
E
A
R 
CCI Correlation 
Coefficient 
1.00 
          
p-value 
           
DM_ 
comp 
Correlation 
Coefficient 
.559
** 
1.00 
         
p-value 0.00 
          
Uncont 
DM 
Correlation 
Coefficient 
.256
** 
.116** 1.00 
        
p-value 0.00 0.00 
         
DMII Correlation 
Coefficient 
.065
** 
-.078** -.176** 1.00 
       
p-value 0.00 0.00 0.00 
        
Hyper-
lipidemia 
Correlation 
Coefficient 
.071
** 
.031* 0.00 .137** 1.00 
      
p-value 0.00 0.03 0.81 0.00 
       
Renal_ 
Disease 
Correlation 
Coefficient 
.613
** 
.225** 0.02 .112** .087** 1.00 
     
p-value 0.00 0.00 0.22 0.00 0.00 
      
Hyper-
tension 
Correlation 
Coefficient 
.203
** 
.080** -0.01 .261** .459** .249** 1.00 
    
p-value 0.00 0.00 0.51 0.00 0.00 0.00           
LoS Correlation 
Coefficient 
.202
** 
.086** .114** 0.02 -.051** .077** 0.02 1.00 
   
p-value 0.00 0.00 0.00 0.14 0.00 0.00 0.28 
    
TOT 
CHG 
Correlation 
Coefficient 
.205
** 
.105** .080** 0.02 -0.02 .098** .034* .654** 1.00 
  
p-value 0.00 0.00 0.00 0.22 0.26 0.00 0.02 0.00 
   
Out 
come 
Correlation 
Coefficient 
.343
** 
.056** 0.00 .136** .066** .218** .117** .165** .205** 1.00 
 
p-value 0.00 0.00 0.96 0.00 0.00 0.00 0.00 0.00 0.00 
  
YEAR Correlation 
Coefficient 
0.01 .029* -0.02 0.00 0.02 0.01 0.01 -0.01 .034* 0.00 1.
00 
p-value 0.61 0.05 0.27 0.90 0.11 0.66 0.72 0.60 0.02 0.99   
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 25. Spearman's rho Correlations for LoS, Total Charge, and Outcome 
    CCI LoS TOTCHG Outcome YEAR 
CCI Correlation Coefficient 1.00 
    
p-value 
     
LoS Correlation Coefficient .202** 1.00 
   
p-value 0.00 
    
TOTCHG Correlation Coefficient .205** .654** 1.00 
  
p-value 0.00 0.00 
   
Outcome Correlation Coefficient .343** .165** .205** 1.00 
 
p-value 0.00 0.00 0.00 
  
YEAR Correlation Coefficient 0.01 -0.01 .034* 0.00 1.00 
p-value 0.61 0.60 0.02 0.99   
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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APPENDIX F: RELATIVE IMPORTANCE OF THE VARIABLES IN 
DTREG ANALYSIS FOR LoS 
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Figure 20. Relative Importance of the Variables in (P) 
 
Variable       Importance 
-------------    ---------- 
AGE                     100.00 
HLS                     18.6 
No_Depression     12.4 
Dementia               9.5 
 
 
Figure 21. Relative Importance of the Variables in (E) 
Variable      Importance 
-----------    ---------- 
SES               100.000 
Patient_Loc        72.124 
Urban_hosp         63.397 
 
 
Figure 22. Relative Importance of the Variables in (N) 
 
   Variable       Importance 
--------------    ---------- 
DM_comp                  100.000 
Renal_Disease             62.5 
Hyperlipidemia             49.4 
DMII                              47.1 
Hypertension                  45.3 
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Figure 23. Relative Importance of the Variables in the overall 
LoS model 
 
Variable       Importance 
--------------    ---------- 
AGE               100.000 
SES                   27.959 
DM_comp               13.252 
Renal_Disease         10.975 
Hypertension          10.559 
Hyperlipidemia        10.552 
DMII                   9.536 
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APPENDIX G: RELATIVE IMPORTANCE OF THE VARIABLES IN 
DTREG ANALYSIS FOR TOTAL CHARGE 
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Figure 24. Relative Importance of the Variables in (P) 
 
Variable       Importance 
-------------    ---------- 
AGE                          100.000 
HLS                            15.2 
No_Depression           11.558 
Dementia                     7.1 
 
 
Figure 25. Relative Importance of the Variables in (E) 
Variable      Importance 
-----------    ---------- 
Patient_Loc       100.000 
SES                     23.709 
Urban_hosp         13.408 
 
 
Figure 26. Relative Importance of the Variables in (N) 
 
Variable       Importance 
--------------    ---------- 
Renal_Disease        100.000 
DM_comp               49.319 
DMII                        27.577 
Hyperlipidemia        19.890 
Hypertension          18.629 
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Figure 27. Relative Importance of the Variables in the 
overall Total Charge model 
 
 
Variable            Importance 
-------------          ---------- 
AGE                    100.000 
Patient_Loc          40.982 
SES                       29.889 
Renal_Disease      13.962 
DM_comp             10.746 
DMII                     10.292 
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APPENDIX H: RELATIVE IMPORTANCE OF THE VARIABLES IN 
DTREG ANALYSIS FOR OUTCOME 
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Figure 28. Relative Importance of the Variables in (P) 
 
Variable       Importance 
-------------    ---------- 
AGE                     100.000 
HLS                       15.802 
No_Depression        11.219 
Dementia                  6.048 
 
 
Figure 29. Relative Importance of the Variables in (E) 
Variable      Importance 
-----------    ---------- 
Patient_Loc       100.000 
SES                30.571 
Urban_hosp         17.680 
 
 
Figure 30. Relative Importance of the Variables in (N) 
 
  Variable       Importance 
--------------    ---------- 
Hyperlipidemia       100.000 
Hypertension          60.302 
Renal_Disease         54.957 
DM_comp               34.036 
DMII                  14.997 
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Figure 31. Relative Importance of the Variables in the overall 
Outcome model 
 
Variable       Importance 
-------------    ---------- 
AGE              100.000 
Renal_Disease        18.193 
Patient_Loc          16.820 
HLS                  11.316 
DM_comp               5.811 
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APPENDIX I: INTERNATIONAL CLASSIFICATION OF DISEASES 
NINTH REVISION (ICD-9) DIAGNOSTIC CODES USED TO EXTRACT 
VARIABLES 
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Table 26. ICD-9 Codes Used to Extract Variables from Original HCUP NIS Data 
Alcohol abuse 
          
 
 29181 30303 30501 53530 7903 2915 30301 30393 4255 5712 9803 2911 
 29182 30390 30502 53531 9800 2918 30302 30500 5353 5713 9808 2912 
 29189 30391 30503 5710 9801 9809 V113  9468 9469 9463 9467 2913 
 30300 30392 3575 5711 9802 9446 9453 9461 9462 
  
2914 
            
 
Arrhythmia 
          
 
 42689 42731 42761 7850 V4501 42613 4271 42742 42789 V450  V533  4260 
 4269 42732 42769 99601 V4502 4267 4272 42760 4279 V4500 V5331 42610 
 4270 42741 42781 99604 V4509 V5339 V5332 
    
42612 
            
 
BMI Underweight 
          
 
 
V850 
          
 
            
 
Cerebrovascular disease 
         
 
 43330 43411 43819 43881 43400 43301 4339 4373 43831 4333 43410 36234 
 43331 4349 43820 43882 43811 4331 43390 438 43832 43812 43850 430 
 4338 43490 43821 4389 43842 43310 43391 4380 43840 43813 43851 431 
 43380 43491 43822 43320 43401 43311 4340 43810 43841 43814 43852 4330 
 43381 436 43830 43321 4341 4332 
     
43300 
            
 
Congestive Heart Failure 
         
 
 40403 4254 4280 42823 42840 40291 40491 4258 42821 42832 42843 39891 
 40411 4255 4281 42830 42841 40401 40493 4259 42822 42833 4289 40201 
 40413 4257 42820 42831 42842 
      
40211 
            
 
Dementia 
          
 
 29012 29021 29041 2908 29410 29011 29020 29040 29043 2941 29420 2900 
 29013 2903 29042 2909 29411 29421 3312 
    
29010 
            
 
Depression 
          
 
 29625 29633 29641 29646 29654 29662 29689 96902 2967 9690 96904  
 29626 29634 29642 29650 29655 29663 2980 96903 29680 96900 96905  
 29630 29635 29643 29651 29656 29664 3004 30112 29682 96901 96909  
 29631 29636 29644 29652 29660 29665 29666 311 29645 29653 29661  
 29632 29640 
         
 
            
 
DM I 
           
 
 25013 25033 25053 25073 25093 25011 25023 25043 25063 25083 25071 25001 
 25021 25041 25061 25081 25091 25012 25031 25051 
   
25003 
            
 
DM II 
           
 
 25022 25042 25062 25082 25080 25010 25032 25052 25072 25092 25040 25000 
 25030 25050 25070 25090 25060 25020 
     
25002 
            
 
DM with CVD 
          
 
 
25071 25072 25073 25070 
       
 
            
 
DM with Eye dis. 
          
 
 
25051 25052 25053 36201 36202 36203 36204 36205 36206 36207 25050  
            
 
DM with Neuropathy 
         
 
 
25061 25062 25063 3572 25060 
      
 
            
 
DM with other compl 
         
 
 25091 25092 25093 25090 
       
 
            
 
DM with Renal Dis. 
          
 
 
25041 25042 25043 25040 
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Drug Abuse 
          
 
 2920 29211 29212 2922 29281 30472 30473 30480 30481 30482 30483 2919 
 29283 29284 29285 29289 2929 30490 30491 30492 30493 30520 30521 29282 
 30401 30402 30403 30410 30411 30522 30523 30530 30531 30532 30533 30400 
 30413 30420 30421 30422 30423 30540 30541 30542 30543 30550 30551 30412 
 30431 30432 30433 30440 30441 30552 30553 30560 30561 30562 30563 30430 
 30443 30450 30451 30452 30453 30570 30571 30572 30573 30580 30581 30442 
 30461 30462 30463 30470 30471 30582 30583 30590 30591 30592 30593 30460 
 9454 9464 9465 9466 9467 3090 3091 9899 V6542 9468 9469 9445 
            
 
HG 
           
 
 
2512 2510 
         
 
            
 
HIV 
           
 
 420 421 422 429 430 7953 79571 7958 V08   449 440 42 
 432 433 439 
        
431 
            
 
Hyperlipidemia 
          
 
 
2724 2720 
         
 
            
 
Hypertension 
          
 
 40210 40300 4039 40401 40411 40201 4030 40311 40400 40410 40490 4010 
 40211 40301 40390 40402 40412 40491 40493 40509 40519 40599 40591 4011 
 40290 4031 40391 40403 40413 40492 40501 40511 4040 4041 4049 4019 
 40291 40310 
         
40200 
            
 
Malignancy 
          
 
 1639 1954 20147 20420 1960 1451 1722 1990 20192 2059 V1091 1400 
 1640 1955 20148 20421 1961 1452 1723 1991 20193 20590 1613 1401 
 1641 1958 20150 20422 1962 1453 1724 1992 20194 20591 1618 1403 
 1642 1960 20151 2048 1963 1454 1725 20000 20195 20592 1619 1404 
 1643 1961 20152 20480 1965 1455 1726 20001 20196 2060 1620 1405 
 1648 1962 20153 20481 1966 1456 1727 20002 20197 20600 1622 1406 
 1649 1963 20154 20482 1968 1458 1728 20003 20198 20601 1623 1408 
 1650 1965 20155 2049 1969 1459 1729 20004 20200 20602 1624 1409 
 1658 1966 20156 20490 1970 1460 1740 20005 20201 2061 1625 1410 
 1659 1968 20157 20491 1971 1461 1741 20006 20202 20610 1628 1411 
 1700 1969 20158 20492 1972 1462 1742 20007 20203 20611 1629 1412 
 1701 1970 20160 2050 1973 1463 1743 20008 20204 20612 1630 1413 
 1702 1971 20161 20500 1974 1464 1744 20010 20205 2062 1631 1414 
 1703 1972 20162 20501 1975 1465 1745 20011 20206 20620 1638 1415 
 1704 1973 20163 20502 1976 1466 1746 20012 20207 20621 193 1416 
 1705 1974 20164 2051 1977 1467 1748 20013 20208 20622 1940 1418 
 1706 1975 20165 20510 1978 1468 1749 20014 20210 2068 1941 1419 
 1707 1976 20166 20511 1980 1469 1750 20015 20211 20680 1943 1420 
 1708 1977 20167 20512 1981 1470 1759 20016 20212 20681 1944 1421 
 1709 1978 20168 2052 1982 1471 1760 20017 20213 20682 1945 1422 
 1710 1980 20170 20520 1983 1472 1761 20018 20214 2069 1946 1428 
 1712 1981 20171 20521 1984 1473 1762 20020 20215 20690 1948 1429 
 1713 1982 20172 20522 1985 1478 1763 20021 20216 20691 1949 1430 
 1714 1983 20173 2053 1986 1479 1764 20022 20217 20692 1950 1431 
 1715 1984 20174 20530 1987 1480 1765 20023 20218 2070 1951 1438 
 1716 1985 20175 20531 19881 1481 1768 20024 20220 20700 1952 1439 
 1717 1986 20176 20532 19882 1482 1769 20025 20221 20701 1953 1440 
 1718 1987 20177 2058 19889 1483 179 20026 20222 20702 20145 1441 
 1719 19881 20178 20580 1990 1488 1800 20027 20223 2071 20146 1448 
 1720 19882 20190 20581 1991 1489 1801 20028 20224 20710 20262 1449 
 1721 19889 20191 20582 1992 1490 1808 20030 20225 20711 20263 1450 
 1886 20072 20267 V1000 V1072 1491 1809 20031 20226 20712 20264 1541 
 1887 20073 20268 V1001 V1079 1498 181 20032 20227 2072 20265 1542 
141 
 1888 20074 20270 V1002 V1081 1499 1820 20033 20228 20720 20266 1543 
 1889 20075 20271 V1003 V1082 1500 1821 20034 20230 20721 2383 1548 
 1890 20076 20272 V1004 V1083 1501 1828 20035 20231 20722 2384 1550 
 1891 20077 20273 V1005 V1084 1502 1830 20036 20232 2078 2385 1551 
 1892 20078 20274 V1006 V1085 1503 1832 20037 20233 20780 2386 1552 
 1893 20080 20275 V1007 V1086 1504 1833 20038 20234 20781 3573 1560 
 1894 20081 20276 V1009 V1087 1505 1834 20040 20235 20782 20066 1561 
 1898 20082 20277 V1011 V1088 1508 1835 20041 20236 2080 20067 1562 
 1899 20083 20278 V1012 V1089 1509 1838 20042 20237 20800 20068 1568 
 1900 20084 20280 V1020 V109  1510 1839 20043 20238 20801 20070 1569 
 1901 20085 20281 V1021 V1090 1511 1840 20044 20240 20802 20071 1570 
 1902 20086 20282 V1022 2038 1512 1841 20045 20241 2081 1881 1571 
 1903 20087 20283 V1029 20380 1513 1842 20046 20242 20810 1882 1572 
 1904 20088 20284 V103  20381 1514 1843 20047 20243 20811 1883 1573 
 1905 20100 20285 V1040 20382 1515 1844 20048 20244 20812 1884 1574 
 1906 20101 20286 V1041 2040 1516 1848 20050 20245 2082 1885 1578 
 1907 20102 20287 V1042 20400 1518 1849 20051 20246 20820 20140 1579 
 1908 20103 20288 V1043 20401 1519 185 20052 20247 20821 20141 1580 
 1909 20104 20290 V1044 20402 1520 1860 20053 20248 20822 20142 1588 
 1910 20105 20291 V1045 2041 1521 1869 20054 20250 2088 20143 1589 
 1911 20106 20292 V1046 20410 1522 1871 20055 20251 20880 20144 1590 
 1912 20107 20293 V1047 20411 1523 1872 20056 20252 20881 1536 1591 
 1913 20108 20294 V1048 20412 1528 1873 20057 20253 20882 1537 1598 
 1914 20110 20295 V1049 2042 1529 1874 20058 20254 2089 1538 1599 
 1915 20111 20296 V1050 20123 1530 1875 20060 20255 20890 1539 1600 
 1916 20112 20297 V1051 20124 1531 1876 20061 20256 20891 1540 1601 
 1917 20113 20298 V1052 20125 1532 1877 20062 20257 20892 2031 1602 
 1918 20114 2030 V1053 20126 1533 1878 20063 20258 2380 20310 1603 
 1919 20115 20300 V1059 20127 1534 1879 20064 20260 2381 20311 1604 
 1920 20116 20301 V1060 20128 1535 1880 20065 20261 2382 20312 1605 
 1921 20117 20302 V1061 V1062 V1063 20121 1928 1611 1923 20120 1608 
 1922 20118 1610 V1071 V1069 20122 1929 1612 
   
1609 
            
 
Moderate or severe liver disease 
        
 
 4561 45620 45621 5722 4560 
      
 
 5724 5728 570 5715 5723 
      
 
            
 
Myocardial infarction  
         
 
 41012 41031 41050 4107 4108 4101 41022 41041 41060 41062 4105 4100 
 4102 41032 41051 41070 41080 41010 4103 41042 41061 41091 41082 41000 
 41020 4104 41052 41071 41081 41011 41030 4106 41072 4109 41092 41001 
 41021 41040 41090 412 
       
41002 
            
 
Patient fall 
          
 
 
E8843 E8844 E8845 E888  E8880 E8881 E8888 E8889 E8842 
  
 
            
 
Peripheral vascular disease 
         
 
 43814 43840 4402 44031 43810 43822 43851 44023 4409 44381 44322 930 
 43819 43841 44020 44032 43811 43830 43852 44024 4410 44382 44323 4373 
 43820 43842 44021 4404 43812 43831 4400 44029 44100 44389 44324 438 
 43821 43850 44022 4408 43813 43832 4401 44030 44101 4439 44329 4380 
 4412 44102 4417 4414 4411 4431 5579 5571 V434  4471 44321 4415 
 4413 44103 4419 
        
4416 
            
 
Renal disease 
          
 
 40402 40501 5836 5881 40310 40411 5824 5852 5889 40391 40490 4030 
 40403 5820 5837 5888 40311 40412 58281 5853 V420  4040 40491 40300 
 4041 5821 585 58881 4039 40413 58289 5854 V451  40400 40492 40301 
 40410 5822 5851 58889 40390 4049 5829 5855 V4511 40401 40493 4031 
 586 V561  5831 5859 V560  V562  5830 5856 V4512 5834 5880 5832 
142 
 
           
 
 40493 V4512 V560  5859 40301 5852 58889 V5631 5881 40402 5855 V5631 
 585 5888 V561  586 40311 5853 5889 V5632 40412 40403 5856 V5632 
 5851 58881 V562  5880 40391 5854 V420  V568  40413 V4511 40492 V568  
 
V451 
          
 
            
 
Rheumatic disease 
          
 
 
7100 7101 7102 7103 7104 7140 7141 7142 71481 71489 725 4465 
            
 
seizures 
           
 
 34570 34571 3458 34580 78031 78032 78033 78039 34590 34591 7803 3457 
 3459 
          
34581 
            
 
            
 
Septicemia 
          
 
 3812 3840 3844 78552 3810 382 3842 388 99591 380 
 
 
 3819 3841 3849 7907 3811 383 3843 389 99592 381 
 
 
            
 
Stroke 
           
 
 43311 4338 43401 V1254 43300 43321 4339 43411 436 43310 43331 430 
 4332 43380 4341 V171  43301 4333 43390 4349 43491 43490 4340 431 
 43320 43381 43410 43400 4331 43330 43391 
    
4330 
TOBACCO USE 
          
 
 30510 30511 30512 30513 3051 
      
 
 
    
98984 
      
 
            
 
Uncont DM 
          
 
 25020 25032 25062 25092 25010 25022 25042 25072 25012 25030 25052 25002 
 25021 25033 25063 25093 25011 25023 25043 25073 25013 25031 25053 25003 
 25083 
          
25082 
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APPENDIX J: ORANGE, OSCEOLA, AND SEMINOLE COUNTY 
STATISTICS  
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Table 27. Orange, Osceola, and Seminole County Statistics Table  
 Osceola Orange Seminole 
 Population % of Total Population % of Total Population % of Total 
Total Population, 2017 estimates 268,685 100% 1,145,956 100% 422,718 100% 
White 190,641 70% 728,795 63% 330,664 78% 
Hispanic or Latino 122,146 45% 308,244 26% 72,457 17% 
Black or African American 30,369 11% 238,241 20% 47,107 11% 
Some Other Race 27,623 10% 77,216 6% 15,692 3% 
Two or More Races 10,900 4% 56,581 4% 15,421 3% 
Asian 7,406 2% 39,325 3% 12,190 2% 
American Indian 1,452 Below 1% 4,532 Below 1% 1,386 Below 1% 
Three or more races 817 Below 1% 2,852 Below 1% 939 Below 1% 
Native Hawaiian Pacific Islander 294 Below 1% 1,266 Below 1% 258 Below 1% 
Population growth estimates       
April 1, 2015 total population estimates 308,327  1,252,396  442,903  
2025 total population estimates 461,900  1,669,000  536,800  
Total population increase 2015-2025 153,573 50% 416,604 33% 93,897 21% 
Hispanic population 2010-2014  growth 32,041 26.2% 57,178 18.5% 12,610 17.4% 
Gender statistics   276 Below 1%   
Total Population, 2016 estimates 265,423  1,112,252  419,203  
Male Population: 129,442 48.8% 546,392 49.1% 202,981 48.4% 
Female Population: 135,981 51.2% 565,860 50.9% 216,222 51.6% 
Age-related statistics       
2015 65 and older 38,251 12.50% 136,704 11% 61,981 14% 
2025 65 and older 66,391 15.50% 215,629 14% 90,084 18% 
2015 Non-Hispanic White 65 and older 19,930 17.6% 79,018 14.5% 48,238 16.8% 
2025 Non-Hispanic White 65 and older 28,778 23.2% 109,729 19.4% 67,952 22.5% 
2015 Non-Hispanic Black 65 and older 3,312 10.5% 21,376 8.1% 4,828 9.5% 
2025 Non-Hispanic Black 65 and older 6,832 14.2% 38,894 11.0% 7,574 12.0% 
2015 Hispanic 65 and older 13,892 9.1% 29,712 8.1% 7,111 8.5% 
2025 Hispanic 65 and older 28,426 11.9% 55,636 10.5% 11,596 10.4% 
Other social statistics       
Veterans, 2011-2015 16,150 19.8% 63,185 20.0% 29,945 12.0% 
Persons with a disability, under age 
65 years, 2011-2015   10.3%  7.2%  6.8% 
Persons  without health insurance, 
under age 65 years   17.6%  15.7%  11.9% 
Median household income (in 2015 
dollars), 2011-2015 44,254  47,943  57,010  
Persons in poverty, percent  18.5%  15.6%  11.5% 
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